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i 
Abstract. 
 
With 170 million infected individuals worldwide, Hepatitis C Virus (HCV) poses 
a global health problem. The primary site of virus replication is the liver, 
leading to progressive disease often culminating in life threatening conditions 
such as hepatocellular carcinoma. HCV has a propensity to persist, with 70-
80% of infected individuals failing to clear the virus.  
 
Intriguingly, HCV associates with host lipoproteins to form lipo-viro-particles, 
these structures are predicted to exhibit the characteristics of both lipoproteins 
and virus particles. Recent evidence suggests that HCV entry is dependent on 
at least three cellular entry factors: a tetraspanin, CD81; a lipoprotein 
receptor, Scavenger Receptor B-I (SR-BI) and the tight junction protein 
Claudin-1. How these molecules coordinate HCV entry and the role(s) of 
particle associated lipoproteins in this process is unknown. This study 
investigates the role of SR-BI in HCV particle attachment and entry. 
 
SR-BI is the major physiological receptor for high density lipoprotein (HDL), it 
is predominantly expressed in the liver and steroidogenic tissue, where it 
mediates the selective uptake of cholesterol to the plasma membrane from 
HDL. HCV particles are believed to interact with SR-BI via the viral envelope 
protein E2, interestingly the SR-BI ligands HDL and oxidised low density 
lipoprotein, enhance and inhibit HCV infection, respectively.  
 
In this study we have investigated the interaction of HCV soluble glycoprotein 
with CHO cells exogenously expressing human SR-BI and, the splice variant, 
SR-BII. We have shown that over expression of SR-BI/II in human hepatoma 
Huh-7.5 cells enhances HCV infection, indicating that SR-BI/II surface 
expression levels limit infection. Furthermore, anti-SR-BI serum inhibits HCV, 
suggesting that it plays an important role in virus attachment and entry.  
 
We demonstrate that a cell culture adapted HCV mutant, with a single amino 
acid change in E2, has a reduced dependency on SR-BI. This altered receptor 
dependency is accompanied by an increased sensitivity to neutralisation by 
soluble CD81 and enhanced binding of recombinant E2 to cell surface 
expressed CD81. The cell culture adapted variant also exhibits an altered 
relationship with lipoproteins and a heightened sensitivity to neutralising 
antibodies. Our data suggest that a balanced interplay between HCV 
particles, lipoprotein components and viral receptors allows the evasion of 
host immune responses. 
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1 
1 Introduction 
1.1 The  disease. 
During the 1970s specific diagnostic tests for hepatitis A, B and D virus(es) 
established that a significant fraction of blood transfusion acquired hepatitis 
was caused by other uncharacterised pathogens. Evidence suggested that a 
single agent, termed non-A non-B hepatitis virus (NANBHV), accounted for up 
to 90% of undiagnosed cases. NANBHV remained largely uncharacterised 
until 1989, when it was demonstrated that cDNA, synthesised from the plasma 
of an infected chimpanzee, could encode for proteins that were recognised by 
antibodies from NANBH patients. The cDNA clones were found to originate 
from an RNA genome of ~10kb containing a single open reading frame, this 
new etiological agent was named hepatitis C virus (HCV) (66, 354). 
 
Expression of HCV encoded peptides in yeast allowed the development of 
immunoassays capable of screening suspected subjects and it soon became 
apparent that large numbers of individuals were infected. The major route of 
infection is via contact with contaminated blood or blood products. 
Consequentially HCV positive antibodies were found in up to 80% of patients 
receiving treatment for haemophilia, ~65% of those with transfusion acquired 
hepatitis and ~60% of intravenous drug users (201, 354). Fortunately, the 
advent of a reliable assay for the detection of HCV allowed the screening of 
blood products, therefore reducing transmission. 
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The occurrence of HCV varies throughout the world, in high prevalence 
regions such as Northern Africa the majority of new infections occur due to 
unsafe therapeutic treatments with contaminated needles. In countries with a 
low incidence of HCV, such as Northern Europe, transmission is 
predominantly between intravenous drug users. Other routes of infection 
include sexual and perinatal transmission, however these are relatively 
inefficient and therefore make only a minor contribution to the prevalence of 
HCV (7, 201). 
 
Characterising the clinical progression of HCV infection has been difficult as 
~70% of infected individuals remain asymptomatic for many years. However it 
has become clear that only 20-30% of subjects clear the virus, with the 
majority of individuals developing a persistent infection (5, 49, 251, 329). In 
these chronically infected patients clinical outcome can vary, ranging from 
mild liver disease through to liver cirrhosis (20-30%) and hepatocellular 
carcinoma (1-7%) (5, 61).  
 
There is a poor understanding of what defines the progression and severity of 
HCV associated liver disease. Pathogenesis can be monitored by the 
detection of markers of hepatic damage such as alanine transaminase (ALT) 
and the inspection of liver tissue (92). However, viral load does not 
necessarily correlate with pathogenesis and in many cases chronic infection 
with HCV is subclinical. There is also limited evidence for cytopathology using 
in vitro models of HCV replication (49, 61, 113, 200). These and other findings 
have led to the broad conclusion that HCV associated disease is 
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predominantly immuno-pathogenic in nature (61). However the field has yet to 
reach consensus, with recent findings using cell culture proficient HCV 
suggesting that the virus may induce cell death (198, 353). Host factors that 
promote severe disease progression include age at infection, alcohol 
consumption and co-infection with human immunodeficiency virus (HIV) or 
hepatitis B virus (HBV) (5).  
 
RNA viruses display broad genetic variability when compared to DNA viruses, 
this is most likely due to the lack of a proof reading ability in RNA polymerases 
(106); HCV is no different. There are 6 major HCV genotypes displaying 
around 30% total divergence (289, 290). A phylogenetic tree displaying the six 
major genotypes of HCV can be seen in Figure 1-1. Although the genotypes 
differ in their geographical distribution and prevalence, their basic virology is 
the same (289) . However there are clinically significant differences in their 
pathogenesis and response to treatment. A common feature of chronic HCV 
infection is steatosis, an abnormal accumulation of lipids within the liver, this is 
particularly prevalent in genotype 3 infected individuals and in these cases 
has been linked to liver fibrosis (266, 267). 
 
For those patients diagnosed before severe liver injury has occurred a 
relatively effective treatment regime is available. Administration of Interferon-
alpha (IFN!), a drug capable of inducing an anti-viral state within cells, in 
combination with the nucleoside anti-metabolite Ribavirin (276, 277), results in 
a sustained virological response in 60-80% of patients with genotype 2 or 3 
4 
infections (12). However in individuals infected with the highly prevalent 
genotype 1, approximately 40% will respond to treatment (12, 96). 
 
Figure 1-1 Phylogentic analysis of HCV  
“Phylogenetic analysis of NS-5 sequences from 76 isolates of HCV, showing 
six major HCV types and subsidiary groupings within some HCV types.” (290)  
 
5 
Aside from considerations of the infecting viral genotype, patient 
characteristics are also important to consider when administering treatment.  
A significant proportion of patients are in ‘hard to treat’ groups, whereby a 
patient’s lifestyle or health makes therapeutic intervention difficult. Such 
individuals include intravenous drug users, who may continually expose 
themselves to HCV and patients with alcohol associated liver damage (278). 
As a result, even in societies with active treatment programs, infection and 
disease remain difficult to control, especially as there is no vaccine currently 
available against HCV (12, 278).  
 
For patients who present with cirrhosis, treatment options are more limited as 
they are typically less responsive to anti-viral therapy, although treatment 
does slow disease progression (275). The prognosis for individuals presenting 
with decompensated cirrhosis or hepatocellular carcinoma (HCC) is poor; with 
5 year survival rates of 50% in untreated patients (275). Liver transplantation 
is generally the only suitable course of action in these cases, however the 
allograft is rapidly re-infected and the clinical features of hepatitis reoccur 
within 100 days (29), as such 5 year survival rates only increase to ~70% 
patients post transplant (275).  
 
About one fifth of patients will experience a self-limiting acute infection, 
culminating in the clearance of the virus. Elucidating the determinants of 
spontaneous resolution has been difficult, as the vast majority of individuals 
who clear infection are asymptomatic (87). However, studies using both 
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animal models and patients identified at the time of exposure to HCV, have 
shed some light on successful immune responses. 
 
A multi-specific and sustained T-cell response associates with viral clearance; 
data suggests a role for both CD4 + and CD8 + T cells (70, 112, 118, 167, 
174, 283, 311). Subjects who have cleared HCV are not necessarily resistant 
to re-infection, with approximately 50% of individuals acquiring protective 
immunity (118, 140, 165, 191, 207). Again, resistance to re-infection is 
correlated with a prolonged and robust T-cell response to HCV infection (118, 
191, 283). 
 
Although the humoral response to HCV is relatively delayed (64), antibodies 
that neutralise HCV infection in vitro can be detected in both acutely and 
chronically infected individuals (182, 210, 327). However, there is limited data 
supporting a role for humoral immunity in viral clearance (87, 140, 182, 245, 
295) and as such there is a lack of consensus over the role of B cells and 
neutralising antibodies in controlling infection. HCV infected patients suffering 
from hypogammablobulinemia are reported to display a rapid and severe 
disease progression with poor response(s) to anti-viral treatment (33), 
suggesting that neutralising antibodies (nAb) may help control HCV. However, 
chronically infected patients exhibit high titre anti-HCV antibodies (87, 140, 
182, 210), suggesting that in the majority of HCV infections nAbs fail to curtail 
viral replication.  
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Current attempts to design a HCV vaccine are focusing on eliciting 
appropriate T-cell activity (43, 61, 154, 298). However two recent publications, 
using mice with humanised livers, demonstrate passive immunity to HCV 
following injection with polyclonal patient immunoglobulin G (IgG) or 
monoclonal anti-E2 antibodies (172, 322), revitalising hopes for a B-cell 
dependent vaccine. 
 
Unfortunately, for the majority of individuals the virus persists in spite of an 
immune response. In many cases the viral load declines as if following an 
acute progression, only to recover over time, establishing a chronic infection 
capable of exhausting T cell responses (154). As discussed earlier, HCV 
induced liver disease is believed to be substantially immunopathogenic in 
nature. Therefore, although a strong T cell response is favourable during early 
infection, once chronicity is established, it may drive rapid progression to liver 
fibrosis and cirrhosis (61, 154). 
 
In 2000 the World Health Organisation estimated there to be 170 million 
infected individuals worldwide; ~3% of the global population. The resulting 
cases of liver disease will number in the tens of millions; HCV is already the 
leading indicator for liver transplantation in the United States (source: Centre 
for Disease Control and Prevention website). Some communities have 
extremely high seroprevelance, for instance ~40% of people in the Nile Delta 
region of Egypt became infected after a poorly conducted schistosomiasis 
vaccination campaign (254). In such areas, the impact of HCV will be 
apparent throughout the whole of society. 
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Recent advances in the field have facilitated detailed in vitro studies of HCV, 
yet without a vaccine or completely effective treatment for the disease, the 
medical, social and economic impetus to understand the virus remains. 
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1.2 An elusive pathogen. 
The emergence of a new human pathogen presents the greatest of 
challenges to modern virology and the discovery of human immunodeficiency 
virus (HIV) in the early 1980s set a precedent for the field. The discipline of 
virology was not quite 100 years old when HIV was first isolated (15). 
However, proficient replication of HIV in vitro allowed the scientific community 
to characterise the virus exceptionally quickly. From the identification of HIV, 
to approval of the first specific therapy (AZT) by the Food and Drug 
Administration took less than 5 years (213, 226) (and FDA website). 
Developments came so quickly that CD4 was identified as the major entry 
receptor before the politics of naming the new pathogen had been resolved 
(178, 199, 272).  
 
As illustrated by HIV, rapid progress in the study of a virus requires an 
appropriate model system capable of supporting virus replication; from its 
inception virology has been dominated by species for which such platforms 
exist.  Early research focused on viruses that infect hosts such as bacteria, 
plants and birds. During the mid 20th century, the advent of mammalian cell 
culture allowed fast and consistent in vitro studies of viral replication. 
However, not all viruses replicate in vitro, which presents a problem when 
studying pathogens with host ranges limited to humans and higher primates 
(78).  
 
In vivo, it is thought that HCV replicates in hepatocytes within the liver. 
However, the hepatocyte is a highly specialised cell type and the liver a 
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complicated organ, therefore it is difficult to recreate the hepatic environment 
in vitro. As a result, HCV within the serum from infected subjects has been 
difficult to propagate in primary human hepatocytes or hepatoma derived cell 
lines (16). As a result, advances in HCV research have been hard fought; the 
suggestion of CD81 as HCV receptor came 10 years after the identification of 
the virus (248). Prior to addressing the virology of HCV, it is important to 
explain the circumstances in which the work was carried out. The following 
section will attempt to outline the technical challenges and breakthroughs 
encountered in the past two decades of HCV research.   
 
There is little consensus over the frequency of HCV positive hepatocytes in an 
infected liver (3, 163, 166), however, the total virus production rates are in the 
order of 1x1012 RNA copies per day (173), resulting in high levels of viremia. 
Consequently, the virus was first isolated from the serum of an experimentally 
infected chimpanzee (66). This is characteristic of the first decade of HCV 
research; without any alternative system, many of the early advances came 
from studies carried out in this ethically and economically controversial animal 
model. Identification of the virus led to the development of reliable diagnostic 
tests allowing the identification of infected patients. Observations of virus 
taken from human plasma shed light on the classification, evolution and 
immunology of HCV, but provided minimal information on basic virology (354).  
 
Early attempts to propagate HCV in primary or immortalised hepatocytes 
proved difficult. HCV replication was severely attenuated and detection could 
only be achieved using reverse transcriptase polymerase chain reaction (RT-
11 
PCR). This technique is highly sensitive making it difficult to discriminate 
between passive cellular uptake of HCV particles and ‘true’ virus entry 
followed by genome replication. Studies were able to eliminate false positives 
by carrying out RT-PCR for both plus strand HCV genomes and negative 
strand replicative intermediates (59, 133, 304). Although these reports 
demonstrated in vitro HCV replication the techniques did not allow detailed 
characterisation of the virus (18). 
 
Investigating the expression and function of viral proteins in isolation was a 
more straightforward task. The existence of gene delivery systems such as 
recombinant plasmids, vaccinia virus and adeno virus, allowed the expression 
of HCV gene(s) in bacterial and mammalian cells (17, 248, 340).  
Observation(s) of the proteins’ enzymatic and regulatory functions contributed 
to a basic understanding of the viral component parts. Indeed, such 
techniques remain a vital tool in the ongoing investigation of HCV. However, 
the absence of in vitro model supporting replication prevented mechanistic 
studies to address how these viral proteins acted in concert. As a result 
elucidating processes such as genome replication or particle assembly 
remained out of reach. 
 
Another limitation of early HCV research was the lack of an infectious clone. 
Studies using chimpanzees or primary human hepatocytes relied on HCV 
positive patient sera as a source of infectivity, however as patient derived 
particles are genetically diverse there was little understanding of what 
constituted an infectious HCV particle. In 1997, Kolykhalov et. al. derived a 
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consensus viral sequence from the serum of a patient carrying highly 
infectious virus. This was used to create a HCV cDNA template for the 
transcription of full length RNA genomes, which, when introduced into 
Chimpanzees, initiated authentic HCV replication (158). This infectious clone, 
termed H77 (Hutchinson, 1977), provided a bone fide consensus HCV 
sequence allowing the field to work towards understanding the determinants 
of infectivity (158, 341). 
 
1999 brought a major technological breakthrough in the form of HCV sub-
genomic replicons (SGR). Comprised of a truncated HCV genome and a 
selectable marker gene, this recombinant construct was capable of 
autonomous replication when introduced into cultured hepatoma cell lines (35, 
183). The SGR system allowed the identification of adaptive mutations that 
promote HCV replication in vitro (35, 37). When introduced in to full length 
HCV, these adaptations permitted the replication of the complete viral genome 
(36, 52). However, these mutations abolished HCV infectivity for chimpanzees 
(52); representing the challenges faced when studying a virus in vitro. The 
replicon system made it possible to inspect the viral and host processes 
necessary for genome replication and maintenance.  It also heralded a new 
era in the search for specific inhibitors of HCV infection, as it was suitable for 
high throughout screening of candidate compounds (76). However, even 
replicons carrying the entire HCV coding region were unable to assemble and 
release infectious particles (35, 37, 183). The process of viral entry and the 
events surrounding particle assembly could not be studied at this time. 
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Within six years of the description of HCV SGR two major advances shed light 
on these elusive stages of the HCV life cycle. Pseudo-particles are 
recombinant virions encoding a reporter gene such as green fluorescent 
protein (GFP). They are constructed around a replication deficient retroviral 
capsid and can be engineered to express the envelope proteins of various 
viruses. In 2003 HCV pseudo-particles (HCVpp) were reported to be 
infectious and allowed the functional characterisation of HCV entry, facilitating 
studies on viral receptors, neutralising antibodies and mechanisms of viral 
fusion with host membranes (24, 82, 130). As work continued with this new 
technique a unique HCV clone, termed Japanese Fulminant Hepatitis-1 (JFH-
1), was isolated. The complete genome of JFH-1 was seen to replicate in vitro 
when introduced in to cultured hepatoma cells (142). Unlike all previous HCV 
genomes tested, infected cells released viable particles that could be used to 
inoculate naïve hepatoma cells, thus completing a full viral life cycle (179, 
328, 351).  
 
HCV capable of in vitro replication are commonly termed HCVcc, as they are 
cell culture proficient; their use has brought about a new and exciting stage in 
the field. Using the JFH-1 non-structural genes as a backbone, numerous 
studies have successfully made infectious chimeric genomes that produce 
virus particles consisting of the structural proteins of other HCV strains (143, 
179, 344). Importantly, HCVcc is infectious in vivo, both in the chimpanzee 
and in immuno-compromised mice carrying humanised livers (141, 180).  
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Current work with HCVcc is focused on defining the determinants of infectivity 
and in particular viral entry, assembly and release. However, efforts are also 
being made to reconcile 15 years of observations on viral subunits with this 
complete model system and to understand how well it represents the situation 
in vivo. The observation that HCVcc replicates in vivo provides gravity to 
findings using this system, however the artificial nature of synthesising virus in 
cultured hepatoma cells will, at best, be a poor mimic of virus produced from 
an infected liver. Consequently, attempts to recreate the hepatic environment 
within a culture flask are ongoing (51). 
 
In conclusion, the resistance of HCV to replicate in vitro has hindered its 
characterisation. However the technological and intellectual tools developed 
to overcome this problem have made an important contribution to the field of 
virology as a whole.  
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1.3 Basic virology. 
Like other members of the flaviviridae HCV encodes three structural proteins 
consistent with a 50-60nm particle, comprised of a capsid, an internal complex 
of core protein and an RNA genome, surrounded by a phospholipid bilayer 
envelope (181, 281). Functional heterodimers of the E1-E2 glycoproteins sit in 
the envelope and mediate virion-target cell interactions (Figure 1-2). 
Interestingly, it is becoming clear that HCV does not fit this classical model of 
flavivirus structure and that it complexes with host components, this is 
discussed in detail later. The HCV RNA genome is a single stranded positive 
sense molecule of 9.6kb in length, comprised of a long coding sequence 
flanked by 5’ and 3’ un-translated regions (UTRs) (181). Particle structure and 
genome organisation suggest that HCV is related to the Flavi and 
Pestiviruses, as such HCV is classed as the sole member of the Hepacivirus 
genus within the Flaviviridae (234, 332).  
Figure 1-2 A cartoon of a Hepatitis C virion.  
Not drawn to scale. 
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HCV targets and enters hepatocytes via at least 3 receptors; CD81, 
scavenger receptor B-I (SR-BI) and claudin-1 (CLDN1) (91, 120, 179), this 
process will be covered in section 1.4. After entry to the cytoplasm the HCV 
genome acts as an mRNA for the production of a single 3000 amino acid 
polyprotein. Unlike some Flaviviruses such as dengue, HCV lacks a 5’ cap 
and as such initiates translation via an internal ribosomal entry site (IRES). 
The IRES is found in the 5’ UTR and contains a series of RNA stem loop 
structures which initiate translation by bringing the 40s ribosomal subunit into 
contact with the viral start codon (18, 251, 318) 
 
The polyprotein comprises 10 proteins, the structural proteins, Core, E1 and 
E2 are found at the amino terminus and the non-structural proteins p7-NS5B 
comprise the remainder. Upon its translation a series of trans-membrane 
domains anchor the polyprotein to the endoplasmic reticulum (Figure 1-2) 
(181, 241). There is an alternate reading frame within the HCV genome 
whereby a ribosomal frameshift within the core region yields a series of 
protein products of unknown function (46, 255). 
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HCV structural proteins: Core. 
HCV core is highly conserved across all HCV genotypes and is found at the N 
terminus of the HCV polyprotein (203), its maturation is dependent on signal 
peptide peptidase cleavage at 2 sites at the C-terminal core-E1 interface 
(306). By analogy to related viruses core is believed to form the nucleocapsid 
of HCV, indeed, core is seen to homodimerise and possesses sites capable of 
binding HCV RNA (203). However there is little information about the 
assembly and structure of HCV capsids, although in vitro expression studies 
suggest that core is capable of self-assembly into icosahedral particles of 30-
40nm (153). In contrast, the ability of core to interact with numerous cellular 
factors, such as tumour necrosis factor receptor-1(203), DEAD box helicase 
DDX3 (192) and dicer (65), is much better understood. These observations 
suggest that core has numerous roles within the replication cycle aside from 
as a virion component. One of the most striking characteristics of core is its 
ability to localise to the lipid droplets (41, 42, 215), intracellular stores of 
neutral lipids and cholesterol, and it has been suggested that this may 
contribute to the occurrence of steatosis in HCV infected individuals (203). 
This characteristic is important for HCV particle assembly and is discussed 
later. 
 
The envelope proteins; E1 and E2. 
Viral envelope proteins mediate particle interaction with cellular receptors and 
in doing so may define the tissue tropism and host range of a virus. Following 
genome translation, HCV E1 and E2 are cleaved by host endoplasmic 
reticulum signal peptidases, thus liberating them from the polyprotein (168, 
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241). E1 and E2 are anchored to the ER membrane by C-terminal 
transmembrane domains, with the ectodomain of either protein extending in to 
the ER lumen (168). Mature HCV envelope proteins exist as non-covalently 
linked heterodimers, and it is believed that the correct conformational folding 
of either protein is dependent on the expression of the other (75, 212). 
Additionally, a host ER chaperpone, Calnexin, has been shown to interact with 
E1 and E2, suggesting that HCV exploits cellular factors during protein 
maturation (48). Apart from anchoring the envelope proteins, the 
transmembrane domains of E1 and E2 are critical for ER retention and 
heterodimer formation (168).  
 
Unlike the envelope proteins of related flaviviruses, E1 and E2 are highly 
glycosylated, with each protein possessing 6 and 11 potential sites 
respectively (168). It is believed that these glycans play a role in protein 
folding, E1E2 interactions with receptors and sensitivity to neutralising 
antibodies (116, 126, 168, 187). Furthermore, the infectivity of a great number 
of viruses is dependent on further proteolytic cleavage of their envelope 
proteins in to active conformations (102). Current evidence suggests that HCV 
E1 and E2 do not undergo such processing (168). The crystal structure of the 
HCV envelope proteins has yet to be solved, thus hindering further dissection 
of their interactions with one another, viral receptors and neutralising 
antibodies. 
 
p7 is also processed by signal peptidases, it is a highly hydrophobic molecule 
that belongs to a broad family of virally encoded ion channels termed 
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viroporins (117). It forms heptameric ion channels in the ER membrane and is 
thought to be important for infectious virion release (119, 296, 297).   
 
HCV non-structural proteins and RNA replication.  
The primary function of the non-structural proteins is genome replication, they 
undergo autolytic processing by viral proteases. Cleavage of the polyprotein 
between NS2 and 3 is achieved by the NS2/3 auto-protease. This frees NS3, 
which in complex with NS4A is the major viral protease, allowing the full 
processing of the remaining non-structural proteins (17, 241). The precise role 
of each non-structural protein is not yet understood, however some are better 
understood than others. For instance, NS5B exhibits all the characteristics of 
a classical RNA dependent polymerase, whereas the role of NS5A is less well 
defined, though it has been implicated in RNA replication, particle assembly 
and virus sensitivity to interferon treatment (301). 
 
Genome synthesis is performed by the NS5B RNA polymerase (28, 340), it 
uses the 3’ hydroxyl group of the positive sense RNA genome to prime the 
production of a negative sense replicative intermediate. This in turn acts as a 
template for the production of nascent HCV genomes (18, 181). However, in 
vitro studies have demonstrated that, when expressed alone, NS5B does not 
display the required level of template discrimination and fidelity (6, 301). In 
fact, HCV genome replication is carried out by NS5B in concert with viral and 
host components; in so called replication complexes (RC). 
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The characterisation of HCV genome replication has primarily been carried 
out in cells expressing sub-genomic replicons, in this system it has been 
estimated that each cell harbours 50-100 RC producing a total of ~1000 HCV 
genome copies per day (252). HCV RC are thought to contain NS3-5B and 
are localised to proteinase and nuclease resistant membranous vesicles 
associated with the ER and golgi network (220, 252, 301). These viral 
components are retained in this environment either by transmembrane 
domains (NS4A,4B,5A and 5B) or through tethering to one another (NS3 to 
NS4A) (220, 301). 
 
Studies to elucidate the role that each non-structural protein plays in the RC 
are on going. NS3, along with a proteolytic domain, contains a helicase 
capable of separating double stranded RNA structures, although it is unknown 
how this contributes to replication (18, 181, 241). NS4B is thought to facilitate 
the formation of a membranous web associated with the ER, believed to be a 
major site of genome replication and particle assembly (90, 301, 334). The 
phosphoprotein NS5A exhibits an RNA binding capacity and numerous cell 
culture adaptations within the protein are seen to enhance RNA replication 
(35, 301). These data suggest an important role for NS5A in the RC, indeed 
its phosphorylation status has been linked to replication efficiency and may be 
an important regulator in the viral life cycle (35, 301, 310). Host factors that 
are thought to contribute to the HCV RC include the DEAD-box helicase 
DDX3 (10), cyclophilin B (125) and miRNA-122 (138). The crystal structures 
of many of the NS proteins have been solved, allowing the design of specific 
inhibitors of viral replication (132). 
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HCV assembly and release is intrinsically linked to the production of very low 
density lipoproteins (VLDL) by hepatocytes (63, 109, 131). Lipoproteins are 
spherical particles that deliver dietary lipids to tissues throughout the body 
(321). The mechanisms by which this occurs are pertinent to the work 
documented in this thesis and will be addressed in greater detail in sections 
1.5 and 1.7. 
 
As discussed earlier, HCV is genetically diverse, however variability is not 
confined to the global level; an infected individual will harbour a population of 
viruses known as a quasispecies swarm (44, 197). A HCV patient will produce 
around 1012 RNA copies per day (229), such a large population will contain 
genetic variants covering each base position of the entire genome (289). 
Although the swarm will display a sequence consensus at any given time, it is 
highly able to respond to new evolutionary pressures as they arise (44). This 
phenomena will become increasingly important as new anti-HCV treatments 
become available. As seen in HIV, quasispecies swarms are quick to develop 
drug resistance if treatment is not managed appropriately (69, 176). Rapid 
quasispecies evolution also contributes to the ability of HCV to continually 
escape host immune responses (85, 327). 
 
Analysis of genetic variation within genotypic or quasispecies populations has 
identified highly conserved and diverse regions of the genome. There is 
pressure to conserve sequences that encode indispensable functions such as 
the IRES or the NS5B polymerase (289). Whereas other regions, particularly 
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in the E1 and E2 glycoprotein genes, display high variation (292, 332). Two 
particular stretches of E2, known as the hypervariable regions I and II (HVR-I 
and HVR-II), are thought to represent neutralisation epitopes under persistent 
immunological pressure (reviewed in (292)).  
 
Our understanding of HCV has expanded greatly since the turn of the century, 
largely due to the technological breakthroughs of HCV replicons and HCVcc in 
vitro assays. However, many processes remain poorly understood, none more 
so than the events leading to HCV internalisation. 
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1.4 Attachment and entry. 
To gain access to a host cell a virus must first attach to its surface and cross 
the cell membrane. The strategies viruses employ to achieve this are wide 
and varied, but in all cases the process can be divided into three generic 
stages. 1) Attachment; this can occur via low specificity interaction(s) with 
ubiquitous cell surface molecules and by high affinity engagement specific 
receptors. 2) Penetration; to replicate the virus must gain access to the cell 
interior. This process always requires transport of viral genetic material across 
a cellular membrane, this can occur at the cell surface or within a sub-cellular 
compartment. 3) Uncoating; in this the final stage of entry, the viral genome 
must become exposed to the appropriate cellular environment to allow 
replication. Delivery of the genome to a non permissive cellular compartment 
can result in non-productive entry (150, 193, 194). 
  
In executing the above processes viruses have to overcome an evolutionary 
dilemma. A virus particle has to be hardy enough to survive the passage to a 
target cell, with all the environmental and immunological hazards that entails. 
However, as it enters a cell it must relinquish its genome as soon as the 
opportunity arises. Therefore to successfully reach and infect a naïve host, a 
virion must exist in an equilibrium between stability and fragility. An ultra-
stable particle may have little trouble surviving the journey only to find its 
genome irretrievably trapped in the capsid. Conversely an ultra-labile particle 
would barely make it out of a host before succumbing to one pressure or 
another (194).   
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The solution reached by a great many species is to exist in a series of meta-
stable conformations. The virus reaches a target cell primed to attach to its 
surface. This primary interaction will trigger conformational change(s), 
preparing the particle for the next stage of entry, whether it be co-receptor 
engagement or penetration to the cell interior (114, 194, 227, 253). Further 
stimuli will prompt step-wise alterations in the particle structure until the 
ultimate event of uncoating. In this way a virus can respond to appropriate 
host surroundings as it moves through an entry pathway. For a general review 
of virus entry strategies see Marsh 2006 (194). 
 
The cellular receptors used by various viruses include signalling molecules 
(102). By interacting with these, some species exert another level of control 
over their entry, inducing signalling events that remodel the target cell to suit 
their purposes. A prime example of such an entry process is the group B 
Coxsackieviruses (CVB). CVBs share a receptor with Adenoviruses; the 
Coxsackievirus and Adenovirus receptor (CAR). CAR is a component of the 
tight junction and as such is inaccessible to CVB as it approaches the apical 
surface of epithelial cells. To overcome this, CVB interacts with the apically 
expressed decay-accelerating factor (DAF) and in doing so induces a 
signalling cascade. The resulting cyto-skeletal remodelling translocates DAF 
to the tight junction, delivering CVB to its co-receptor. Subsequent CVB-CAR 
interaction induces a conformational change allowing particle penetration to 
the cell interior (71). The details of HCV attachment and entry are poorly 
understood. However from what little we know, the specific events involved 
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may be as complicated and fascinating as the pathway employed by viruses 
such as CVB.  
 
1.4.1 Co-receptors 
The attachment and entry of HCV is dependent on at least three host cell 
molecules, or receptors, the following section will detail their chronological 
discovery and what we know of their relationship with HCV. 
 
CD81 
As a member of the tetraspanin family of integral membrane proteins, CD81 
has 2 extracellular (EC) loops anchored by 4 transmembrane domains, it is 
widely expressed throughout the human body (177). Tetraspanins play a role 
in membrane organisation, forming cholesterol dependent tetraspanin webs. 
These act as a scaffold for the formation of functionally active membrane 
domains (40). CD81 facilitates signalling events involved in immune cell 
differentiation, adhesion and activation, it also plays a role in the acrosome 
reaction necessary for sperm-egg fusion (177, 268). CD81 has been 
implicated in the infection of hepatocytes by Plasmodium, the causative agent 
of malaria (288). 
 
The search for putative HCV receptors began with the development of a 
soluble form of the major HCV envelope protein (sE2). Pileri et al noted that 
although sE2 bound to cells of human origin it would not bind to murine cells 
(248). They utilised sE2 to screen a human cDNA library expressed in mouse 
fibroblasts; the cDNA clone encoding CD81 successfully conferred sE2 
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binding to mouse cells. sE2 interacted with the large extracellular loop (LEL) 
of CD81 and could be perturbed by anti-HCV sera (248, 336). Systems 
supporting HCV entry were not available at this time and studies continued to 
characterise recombinant forms of E2 and CD81. Comparison of human CD81 
to those of other mammals unable to bind sE2, supported earlier data that the 
LEL of CD81 is important (99). Subsequent studies using alanine scanning 
mutatagenesis within these regions of CD81, identified positions L162, I182, 
N184 and F186 to be involved in the interaction with E2 (83, 84, 99, 127). 
 
The advent of the HCVpp system to measure viral entry (24, 82, 130) allowed 
unequivocal demonstration of the importance of CD81 in HCV infection. 
Soluble recombinant forms of CD81 LEL, anti-CD81 mAbs and siRNA 
knockdown of CD81 efficiently inhibited HCVpp infection, confirming its 
importance for viral entry (130, 171, 348). Furthermore, expression of CD81 in 
the CD81 negative HepG2 hepatoma cell line rendered the cells permissive to 
HCVpp infection (171, 202, 348). These observations were soon corroborated 
using HCVcc system (179, 328). HCVpp bearing diverse glycoproteins 
showed varying abilities to infect HepG2 cells expressing CD81, suggesting 
genotype specific differences in E2-CD81 interaction or the involvement of 
other receptor components, however CD81 was an absolute requirement for 
infection in each case suggesting a critical role in HCV entry (171, 202). 
 
An interesting study by Flint et. al. demonstrated that although CD81 from 
African green monkey and hamster showed little or no interaction with sE2, 
both were capable of supporting HCVpp and HCVcc infection when expressed 
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in HepG2 cells (101). These data indicate that using recombinant soluble 
proteins to measure E2-receptor interactions can be a poor model of infection. 
They also established that soluble CD81 LEL neutralisation of HCVpp occurs 
after virion binding to target cells (101), suggesting that CD81 is not the 
primary HCV attachment receptor, a view supported by other findings (31, 91, 
346). 
 
The use of anti-E2 mAbs and comparison of diverse envelope proteins 
allowed the identification of putative CD81 recognition domains within the 
major HCV glycoprotein. Mutagenic studies within these regions has both 
confirmed and eliminated candidate residues. The currently accepted CD81 
binding regions are 436-443, 527-535 and 612-619, residue 420 is also 
involved (81, 99, 237, 265). However, without a crystal structure of HCV E2 it 
remains unclear how these distant regions engage CD81 and whether other 
receptors are required to promote CD81 interaction. Antibodies that recognise 
sites within CD81 binding regions are neutralising and work to develop a 
vaccine that targets these epitopes is ongoing (145, 147, 236, 237, 307). 
 
Scavenger receptor B-I (SR-BI) 
SR-BI is a multi-ligand lipoprotein receptor, it is expressed throughout the 
body but is predominantly found in the liver and steroidogenic tissue (161). It 
resides at the plasma membrane, with two transmembrane domains 
separated by a large extracellular region responsible for ligand binding (161). 
Its functions are varied and will be covered in more detail in a later section. 
However its major role within the liver is the uptake of cholesterol from high 
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density lipoprotein (HDL), allowing selective sorting and if necessary excretion 
into the bile (161, 286). 
 
Identification of SR-BI as a HCV co-receptor also relied on recombinant viral 
glycoproteins. Scarselli et. al. noted that sE2 bound to CD81 negative HepG2 
cells, indicating another means of attachment (274). sE2 pull down of 
biotinylated HepG2 cell surface molecules, isolated an 82kDa glycoprotein 
found to be SR-BI. To confirm this Chinese hamster ovary (CHO) cells were 
transfected to express human SR-BI and were found to bind HCV sE2 (274).  
 
E2-SR-BI interactions are currently believed to occur via HVR1, as deletion of 
this region and anti-HVR1 mAbs ablate sE2 binding to CHO SR-BI cells (26, 
274). HCVpp virus lacking the HVR ("HVR) are poorly infectious (25), 
however it has been shown that "HVR HCV RNA is still infectious when 
inoculated in Chimpanzees, although this was accompanied with the rapid 
occurrence of adaptive mutations within the envelope proteins (104). Maillard 
et. al. reported that patient serum derived HCV may interact with SR-BI via 
particle associated lipoproteins and this may provide an explanation for why 
"HVR HCV is still infectious (190). 
 
The major SR-BI ligand HDL enhances HCVpp and HCVcc infection (80, 
325), although not all HCV genotypes respond to treatment (326).  This 
phenotype is dependent on HVR1 interaction(s) with SR-BI and on the ability 
of SR-BI to transfer cholesterol from lipoproteins (25, 80, 324, 325). The 
mechanism by which this occurs is still unclear, however it is thought to 
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involve the HDL component apoprotein C-I (ApoC-I) (79). It has been 
suggested that HDL enhancement offers partial protection from anti-
glycoprotein neutralising antibodies by increasing the speed of particle uptake 
(80, 325). Conversely, another SR-BI ligand, oxidised low density lipoprotein 
(oxLDL) inhibits HCV infection, however this does not occur via perturbation of 
E2-SR-BI interactions (326). Anti-SR-BI antibodies have been reported to 
reduce HCV infection as does SR-BI siRNA knock down, however the 
sensitivity to treatment is genotype specific (60, 120, 139, 171, 346). Over 
expression of SR-BI in Huh-7.5 cells enhances HCVcc infection (120), 
suggesting that its expression levels limit viral entry, this work is covered in 
the following chapters.  
 
sE2 binds to SR-BI from the tree shrew tupaia but does not interact with  
murine SR-BI, furthermore primary tupaia hepatocytes are permissive to HCV 
infection (19). This suggests that SR-BI may determine the host range 
exhibited by HCV. The lack of an SR-BI negative cell line that supports HCV 
RNA replication has hindered attempts to characterise its role in infection. 
Consequently there is no definitive proof that SR-BI is an absolute 
requirement for HCV attachment and entry. However, the field is still 
developing and current findings suggest that SR-BI plays an important role in 
the HCV life cycle. 
 
Claudin-1 
The function of all organs within the human body are dependent on the 
selective and directional sorting of solutes and metabolites, for instance the 
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blood brain barrier is permeable only to relatively small molecules such as 
sugars. This is achieved by tissue polarisation; the cells found within tissue 
layers have distinct ‘top’ and ‘bottom’ surfaces, termed apical and basolateral 
respectively. Each surface will have a specific protein expression profile suited 
to the tasks it performs. The maintenance of tissue integrity and polarity is 
largely mediated by tight junctions. These are lateral structures that form at 
cell junctions, binding adjacent cell membranes together in a way that 
prevents the free movement of solutes across the tissue layer. Tight junctions 
are comprised of transmembrane proteins such as occludins, claudins, 
junctional adhesion molecules and e-cadherin, these interact with the cell 
interior via cytoplasmic partners, for instance ZO-1 and cingulin (27, 160). 
Other types of cell junctions include, gap and adherence junctions which 
mediate selective solute exchange and the attachment of adjacent cells, 
respectively (74). 
 
There are 24 members of the claudin family and they share a basic structure 
with tetraspanins; 4 transmembrane domains anchoring 2 extracellular (EC) 
loops. The larger of the loops, EC1, is responsible for sealing the tight 
junctions and the formation of selective ion channels, whereas the other 
mediates lateral and oppositional organisation of the protein (160). 
Intracellular domains interact with adaptor molecules that tether the proteins 
to the cytoskeleton (160). The liver is a composed of highly polarised units 
called lobules and claudin-1 (CLDN1) is expressed in the tight junctions 
between hepatocytes that maintain these structures (157, 160). 
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The discovery of CLDN1 as a HCV receptor, unlike CD81 and SR-BI, utilised 
the HCVpp system. Evans et. al. expressed a cDNA library from a permissive 
hepatoma cell line in CD81+/SR-BI+ human embryonic kidney cells and 
screened the transduced cells for their ability to support HCVpp infection (91). 
Consecutive rounds of screening identified CLDN1 as a HCV co-receptor. 
This was confirmed by HCVcc infection of 293T cells expressing CLDN1 (91). 
Whereas siRNA silencing of CLDN1 in hepatoma cells rendered the cells non-
permissive for viral infection (91, 205, 350) . 
 
Generation of chimeric CLDN1 molecules expressing domains of CLDN7 
demonstrated that the CLDN1 EC1 domain is necessary for receptor activity. 
Only five residues differ between the CLDN1 and CLDN7 EC1 domains, 
mutation at these sites revealed that residues I32 and E48 are critical for 
CLDN1 receptor activity (91). Due to the unavailability of an appropriate anti-
CLDN1 antibody, a flag tag was inserted into the CLDN1 EC1, permitting the 
inhibition of HCVpp infection with an anti-flag antibody. Anti-flag or anti-CD81 
mAbs were used to inhibit HCV entry at various time points, demonstrating 
that HCV-CD81 interaction precedes CLDN1 engagement. The anti-flag mAb 
also inhibited E1E2 dependent fusion suggesting that CLDN1 facilitates the 
molecular events preceding particle penetration (91). 
 
In the year following the identification of CLDN1 as a HCV receptor, studies 
have indicated that 2 other claudin family members, CLDN6 and CLDN9, 
confer permissivity to 293T cells (205, 350). It is not yet clear how CLDN1/6/9 
33 
act as receptors for viral entry and studies to characterise their interaction with 
HCV are ongoing (91, 342). Figure 1-2 depicts the HCV receptor complex.  
34 
 
Fi
gu
re
 1
-2
 C
el
lu
la
r r
ec
ep
to
rs
 fo
r H
C
V.
  
Th
e 
re
ce
pt
or
 a
ct
iv
ity
 o
f 
C
D
81
 a
nd
 C
LD
N
1 
is
 d
ep
en
de
nt
 o
n 
cr
iti
ca
l 
re
si
du
es
 w
ith
in
 t
he
 L
E
L 
an
d 
E
C
1 
do
m
ai
ns
, r
es
pe
ct
iv
el
y.
 T
he
 re
gi
on
s 
of
 S
R
-B
I r
es
po
ns
ib
le
 fo
r r
ec
ep
to
r a
ct
iv
ity
 h
av
e 
ye
t t
o 
be
 re
po
rte
d.
  
 
35 
 
1.4.2 Attachment factors 
The true definition of a virus receptor is somewhat debatable. There are some 
types of molecules used by viruses to aid tethering to the cell surface that are 
not thought to initiate specific entry. These so called attachment factors are 
important for infection as they bring a virus into proximity with the cell surface 
and its entry receptors. However virus interaction with them may be of low 
specificity and have little role in viral entry (102, 194). The following section 
discusses molecules employed by HCV that, as current understanding allows, 
fall into this category.   
 
Heparan sulphate 
Glycosaminoglycans (GAGs) are polysaccharide moieties that are post-
translationally added to certain types of protein know as proteoglycans (30). 
Heparan sulphate (HS) is a long chain, highly sulphated GAG, that is 
commonly found on proteoglycans in the extracellular matrix and at the 
plasma membrane and offers a ubiquitous target for viral attachment (30, 
102). 
 
HCV E2 association with HS (20, 22), is believed to occur via electrostatic 
interactions involving basic residues possibly including the HVR (20, 22), 
although some evidence disputes this (57). Soluble highly sulphated HS 
inhibits the binding of E2 to cells and reduces HCVpp entry, as does removal 
of cellular HS by heparinase (20, 22). However, to date there is little evidence 
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that these treatments inhibit authentic HCV particle infection, leaving the 
importance of HS in some question (221). 
 
L/DC-SIGN 
Liver or dendritic cell specific intercellular adhesion molecule 3-grabbing 
nonintegrins (L/DC-SIGN) are C-type lectins capable of recognising 
glycoproteins via mannose residues (186). They are believed to play a role in 
liver sinusoidal/dendritic cell interactions with immune cells by virtue of their 
ability to bind Inter-Cellular Adhesion Molecules (ICAMs)  (149). DC-SIGN has 
also been implicated in the attachment and entry of HIV, Dengue and severe 
acute respiratory syndrome (SARS) corona virus (62, 111, 149, 175, 309). 
 
L/DC-SIGN facilitate binding of sE2, HCV virus-like particles (HCV VLPs), 
HCVpp and patient serum derived virions, and this can be inhibited using 
exogenous mannan ligand or by L/DC-SIGN antibodies (23, 107, 185, 187, 
250). Dendritic cells (DCs) are central to antigen processing and presentation, 
it has been shown that HCV VLPs bind to DC-SIGN on the surface of DCs 
and in doing so avoid targeting to the lysosome, suggesting an ability to 
evade the antigen processing pathway (188). Liver sinusoidal cells can bind 
HCV sE2 via L/DC-SIGN, although they are not permissive to HCVpp infection 
(162). However, pseudo-particles bound to L/DC-SIGN can be cross-
presented to hepatoma cells (93, 185). The prevailing hypothesis is that these 
molecules do not take part in HCV entry but allow concentration of virions on 
dendritic cells or liver endothelium allowing presentation to permissive 
hepatocytes (162). 
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1.4.3 Endocytosis and fusion 
After successful binding to a target cell a virion must cross a cellular 
membrane to gain entry to the interior. HCV has an enveloped particle and 
most likely achieves this by fusion of its own lipid membrane with that of the 
host cell, allowing free passage of the capsid into the cytoplasm (150). Viral 
fusion events occur either at the plasma membrane (e.g. HIV) or in an 
intracellular compartment after endocytosis (e.g. Influenza) and normally 
involve a conformational change in an envelope protein exposing a fusion 
peptide (150, 194). These hydrophobic domains insert into the target 
membrane as homotrimers, allowing the formation of a ‘hair-pin’ structure that 
bring the virus and host lipid bilayers into contact, as reviewed by Kielian and 
Rey (150).  
 
The penetration of a number of viruses has been well characterised and as 
such theorising over the fusion strategy employed by HCV was possible long 
before an in vitro model of entry was available. For instance proteomic 
analysis of HCV E1 suggests it is a class II fusion protein similar to that of 
another Flavivirus, tick-borne encephalitis virus (108). Using well established 
tools for investigating virus fusion, the HCVcc/pp systems are now allowing 
the elucidation of HCV fusion events. 
 
Class II fusion proteins typically initiate virion penetration after endocytosis in 
acidified endosomal compartments; low pH being necessary for the exposure 
of the fusion peptide (150, 195). Indeed compounds that disrupt the regulation 
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of pH within the endosome inhibit HCVpp infection, consistent with this model 
(34, 68, 130, 206). The initial endocytosis of an enveloped virus can occur in a 
number of ways, for instance via clathrin or caveolae dependent pathways 
(195). HCV endocytosis is via the clathrin pathway as demonstrated using 
dominant negative and siRNA suppressors of the clathrin heavy chain protein 
(34, 68, 206). The virus is thought to initiate fusion in the early endosome, 
although unlike other similar viruses there appears to be a delay between 
endocytosis and full penetration, suggesting that low pH alone is not sufficient 
to trigger fusion and that other molecular events, such as receptor 
engagement, are necessary (206). In support of this low pH pre-treatment 
does not affect the infectivity of HCVcc particles (317).  
 
We know very little of the precise molecular events involved in HCV mediated 
fusion other than pH and temperature dependence and possible requirement 
for prior interaction with CD81 and CLDN1 (91, 155, 169). Identification of 
membranotropic regions within E1 and E2 have provided numerous putative 
fusion domains (238, 242-244). Although mutagenesis studies have shown 
some regions to be necessary for HCVpp fusion and/or infection, a consensus 
has not yet been reached (155, 170, 242). Interestingly, Dreux et. al. 
established that enhancement of HCV infection by HDL involves the 
incorporation of a lipoprotein component, ApoC-I, into HCV particles. This in 
turn increases HCVpp-liposome membrane mixing (79) suggesting that HCV 
may sequester host factors to facilitate fusion. 
 
39 
1.4.4 Co-receptor interplay and localisation. 
Although there is some evidence to support extra hepatic reservoirs of HCV 
(72), the primary site of HCV replication is the liver, however it is unknown 
what determines this tropism. The major HCV co-receptors discussed above 
are expressed to varying degrees throughout the entire body, furthermore 
some hepatic cell lines expressing all three remain non-permissive to HCVpp 
(91). In this respect they can be regarded as necessary but not sufficient for 
HCV infection. The initial interpretation of this observation is that there is 
another co-receptor yet to be identified; indeed this possibility is under 
continuous scrutiny. However other explanations must also be considered and 
one such candidate for determining liver tropism is tissue specific co-receptor 
interplay and localisation. The information and tools necessary to address co-
receptor interactions and organisation have only recently become available 
and as such it remains a burgeoning field of interest. This section will detail 
our as yet limited understanding of how the HCV co-receptors behave within a 
permissive cell.   
 
Current evidence suggests that CD81 is not the primary HCV receptor (31, 91, 
101, 346). There is little information as to when SR-BI is involved, although it 
too may play a role after virus attachment to factors such as heparan sulphate 
(346). It has been demonstrated that anti-CD81 and SR-BI antibodies act 
synergistically to inhibit HCV infection, suggesting an interplay between these 
molecules in defining viral entry (139, 346).  
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The entry of a great many viruses is dependent on cholesterol levels within 
host cell and particle membranes (150, 194). Indeed depletion of cholesterol 
by treatment with methyl-# cyclo-dextran inhibits HCV infection although 
reports differ as to whether this occurs via relocalisation of CD81 or CLDN1 
(47, 139). SR-BI is unique in its ability to deliver cholesterol from lipoproteins 
directly to the plasma membrane (161). Recent publications implicate SR-BI in 
the infection of hepatocytes by Plasmodium (262, 339), the CD81 dependent 
causative agent of Malaria. It was shown that the delivery of cholesterol to the 
plasma membrane by SR-BI promotes CD81 localisation to the cholesterol 
dependent tetraspanin domains, facilitating Plasmodium sporozoite invasion 
(339). It is possible that SR-BI may contribute to HCV entry in a similar 
manner by introducing cholesterol at defined locations within the membrane. 
 
Current data suggests that CLDN1 acts at a point downstream of virus-CD81 
engagement (91), however the transition of HCV between its receptors is not 
yet understood. Populations of CLDN1 and CD81 have been shown to co-
localise in hepatoma cells and fluorescent resonance energy transfer (FRET) 
analysis indicates they are within ~5nm of one another (124), suggesting the 
formation of CLDN1-CD81 complexes. Although there is no evidence that 
HCV infection alters CD81-CLDN co-localisation, addition of recombinant 
E1E2 envelope proteins reduces the distance between CLDN1 and CD81 as 
measured by FRET (124).  
 
The summer of 2008 brought two publications that provide evidence of 
signalling events involved in HCV entry. Farquhar et. al. have shown that  
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inhibition of protein kinase A (PKA) activity in target cells reduces HCVcc and 
HCVpp infection, correlating with a re-localisation of CLDN1 into intracellular 
vesicles (94).  Brazzoli et. al. used siRNA silencing of Rho family GTPases to 
abrogate HCV infection, they attributed this phenotype to the ability of HCV E2 
to induce Rho dependent re-localisation of CD81, suggesting that HCV may 
be able to orchestrate molecular events necessary for viral entry (47). 
 
Hepatocytes, as discussed earlier, are a polarised cell type and reside in a 
highly ordered three dimensional structure, it is unknown what implications 
this has for HCV infection. Whether the cultured hepatoma cells used for in 
vitro HCV infection are capable of polarisation remains a controversial topic 
(204, 342). In this respect they may represent a poor mimic of the hepatic 
environment and work has begun to address HCV receptor expression in 
polarised systems.  
 
The most comprehensive study thus far involved the infection of Caco-2 
(colorectal adenocarcinoma) cells by HCVcc/pp (204). Although these cells 
express the 3 major HCV co-receptors they are minimally permissive to 
infection. However, this is balanced by the fact that Caco-2 cells are a widely 
recognised model of a polarised cell and provide a stepping stone to 
understanding HCV interactions with hepatocytes. The expression levels and 
localisation of the HCV receptors altered greatly depending on the degree of 
Caco-2 polarisation. HCVpp entry occurred preferentially via the apical 
surface and disruption of tight junctions enhanced infection, suggesting 
laterally located co-receptors are inaccessible to the virus in Caco-2 cells 
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(204). Other investigations have correlated CLDN1 junctional localisation to 
HCV permissivity, however these studies were carried using minimally or non-
polarised cell types (342). The search for an appropriate polarised hepatic cell 
line is ongoing. 
 
A recent report has raised the prospect of tissue specific factors that may 
interfere with the interaction of HCV and its co-receptors (261). The 
tetraspanin web in which CD81 resides contains numerous partner molecules 
that contribute to the characteristics of the membrane domain. EWI-2 is a 
member of the immunoglobulin super-family and contains a unique glutamine-
tryptophan-isoleucine (EWI) motif, it is a major partner of CD81 and is 
believed to mediate interactions between the web and underlying cytoskeleton 
(271). Interestingly a tissue specific EWI-2 cleavage product, EWI-2wint (EWI-
2 without its N-terminus), is able to block HCV E2 interaction with CD81 and 
introduction of EWI-2wint into permissive hepatoma cells reduces HCVcc/pp 
infection (261). The proteolytic cleavage necessary for EWI-2wint expression 
does not occur in permissive cells, suggesting that an inhibitory protein may 
determine HCV liver tropism.  
 
The process of characterising the series of virus-receptor and receptor-
receptor interactions necessary for HCV infection has only just begun; the 
rather disparate nature of our current knowledge reflects this. However, as the 
field develops we will be able to consolidate our understanding of the complex 
relationships within a permissive cell allowing a global perspective on HCV 
attachment and entry. 
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1.5 Lipoproteins 
Since 1992 there has been a steady accumulation of evidence implicating 
lipoprotein metabolism in the HCV life cycle, specifically during viral entry, via 
receptors such as SR-BI and the subsequent secretion of particles from 
infected cells (25, 109, 312). Therefore prior to discussing these matters, the 
following section will give an overview on the structure, physiological 
importance and metabolism of lipoproteins. The majority of the material 
covered is summarised from Lipoproteins in Health and Disease by Betteridge 
et. al. (32) and Biochemistry of Lipids, Lipoproteins and Membranes by Vance 
et. al. (321). 
 
Lipids play an essential role in the maintenance of the human body, however 
they are by their very nature insoluble in water, making their transport 
problematic. Specific tissues overcome this by complexing them with proteins 
into organised soluble structures known as lipoproteins, which circulate in the 
plasma. Although diverse in nature, all lipoproteins have the same basic 
structure; a core of neutral, therefore hydrophobic, triglycerides (TG) and 
cholesterol esters, surrounded by a monolayer of polar phospholipids. The 
protein component of these structures, termed apoproteins, sit in the 
monolayer penetrating the central core to varying degrees. Whilst in the 
circulation, these apoproteins determine the interaction of lipoproteins with the 
mediators of their metabolism (Figure 1-3). 
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Figure 1-3 The basic structure of a lipoprotein 
 
 
 
 
Table 1-1 The major species of lipoprotein.  
Lipid:protein ratios are calculated by weight. 
Table 1-2 Major forms of apoprotein. 
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Lipoproteins exist in a dynamic spectrum of size and composition, 
consequently their classification can be approached in a number of ways, for 
example by apoprotein content. However, as lipids have a lower density than 
proteins, lipoproteins can also be separated by their lipid to protein ratio via 
buoyant density centrifugation, allowing simple classification of distinct 
subsets. They range from large, triglyceride rich Chylomicrons through to 
small, cholesterol and protein rich High Density Lipoproteins (summarised in 
Table 1-1). 
 
The apoproteins are a diverse class of molecule that contribute to lipoprotein 
structure and mediate their specific interaction(s) with a wide array of 
enzymes and receptors. They fall into two subsets; exchangeable and non-
exchangeable. The former are soluble proteins that readily transfer between 
lipoproteins in circulation, the latter are large insoluble proteins that remain 
within a lipoprotein for the duration of its catabolism. The non-exchangeable 
ApoB proteins are the major structural elements of CM, VLDL and LDL. The 
exchangeable forms, such as ApoC, have transient relationships with 
lipoproteins, directing their traffic and hydrolysis in response to the 
requirements of specific tissues and dietary conditions (Table 1-2).  
 
Lipids need to be delivered to tissues in a highly specific manner as 
inappropriate or excessive lipid delivery is pathogenic, as seen in coronary 
heart disease. An array of lipase enzymes and cellular receptors allow 
different tissue types to extract the appropriate lipids in the correct amounts 
from the same circulating pool. To meet these varied demands, there is an 
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intricate network of interactions between the lipoproteins, apoproteins, 
enzymes and receptors, which naturally lends it self to adaptability. It would 
be inappropriate to cover this in great detail here, therefore the following 
paragraphs summarise the journey of dietary lipids entering and exiting the 
lipoprotein pathway. 
 
Upon entering the intestine, dietary lipids are emulsified, taken up by 
enterocytes and used to assemble CM, each containing a single ApoB-48 
molecule. CM enter circulation via the lymphatic system and quickly acquire 
exchangeable ApoC-II molecules. ApoC-II facilitates the action of lipoprotein 
lipase (LPL), an enzyme that releases fatty acids from TG. As the TG is 
depleted from CM ApoC-II is replaced by ApoE, which facilitates the uptake of 
CM by the liver, delivering the remaining TGs and cholesterol to the hepatic 
lipoprotein assembly pathway.  
 
As the site of VLDL assembly the liver is central to controlling plasma 
lipoprotein concentrations. Microsomal triglyceride transfer protein (MTP), 
loads ApoB-100 molecules with lipid to form nascent VLDL particles. As these 
move through the secretory pathway they become increasingly lipidated a 
process facilitated by the addition of ApoE (122). ApoB-100 is constitutively 
produced by hepatocytes however poorly lipidated forms are degraded before 
secretion. Once in the circulation the action of lipases such as LPL depletes 
VLDL of tri-glycerides, leading to a gradual enrichment of cholesterol and loss 
of the exchangeable apoproteins. This culminates in LDL, a smaller, more 
dense particle. LDL is the major carrier of cholesterol throughout the body, 
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and delivers its cargo via the well characterised clathrin dependent LDL 
receptor (LDLR) pathway.  
 
Unlike TGs, which are routinely loaded into adipocytes, excess cholesterol 
cannot be stored. Cholesterol deposits are pathogenic, leading to 
atherosclerosis and coronary heart disease and thus plasma cholesterol 
levels must be maintained at a steady state. HDL plays an important role in 
this process; it can be seen as carrying cholesterol out of the body, a process 
often referred to as reverse cholesterol transport. 
 
HDL is formed extracellularly around ApoA-I molecules. ApoA-I is secreted 
from the liver and intestines and it is loaded with excess cholesterol by 
membrane proteins such as the ATP binding cassette transporter (ABCA-I), 
forming disc shaped precursor HDL particles. ABCA-I is expressed throughout 
the body, however it is found at particularly high levels on macrophages, as 
they are important for clearing excess cholesterol from arterial atherogenic 
lesions.  These particles mature into spherical HDL particles which then 
deliver cholesterol esters to the liver via SR-BI, permitting excretion in the bile, 
this process will be covered in detail later.  
48 
1.6 Scavenger receptor B-I. 
SR-BI is a central player in the regulation of cholesterol levels, the following 
section details SR-BI in the context of lipoprotein metabolism. 
 
Also known as Cla-1, SR-BI was first described in 1993 by Calvo et. al. due to 
its homology to CD36, another receptor involved in lipoprotein metabolism 
(58). 509 amino acids in length, SR-BI has two trans-membrane domains 
bridging intracellular N and C termini with a large extracellular loop 
responsible for ligand binding (286). SR-BI is predominantly expressed within 
the liver and steroidogenic tissue (161), where it mediates the transfer of 
cholesterol from lipoproteins, it also plays a role in the disposal of cholesterol 
from foam cells within atherosclerotic lesions (287). 
 
The expression of SR-BI on the surface of hepatocytes is regulated by an 
interaction with the scaffolding protein PDZK1 (156, 285), via PDZ binding 
domains within its C-terminus (135). In turn PDZK1 is regulated in response to 
hormonal stimuli by phosphorylation of key serine residues (225). Notably, 
PDZK1 does not modulate SR-BI localisation in steroidogenic organs (156), 
reflecting the differing cholesterol requirements of specific tissues. 
 
In 1996 Acton et. al. discovered SR-BI to be the previously unidentified 
physiological receptor for HDL. SR-BI is capable of selective cholesterol 
uptake from HDL (2), a process whereby cholesterol esters are delivered 
directly to the plasma membrane independent of the apoprotein component of 
HDL (11). Swarnakar et. al. reported that SR-BI also mediates selective 
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uptake of cholesterol from LDL (303). The membranous environment in which 
SR-BI resides appears to determine its activity in respect of selective uptake; 
association with lipid rafts favours selective uptake from LDL whereas uptake 
from HDL occurs preferentially within disordered regions of the membrane 
(258). It is believed that HDL and LDL possess alternative modes of binding to 
SR-BI, possibly via distinct domains. However, HDL can compete for the 
binding of LDL, whereas LDL only partially inhibits HDL binding, suggesting a 
complex ligand-receptor interplay (161).  
 
Although originally thought to be a strictly non-endocytic receptor, it has 
become clear that SR-BI is capable of endocytosing both HDL and LDL 
independent of selective uptake (231, 287, 300). In the case of HDL, whole 
particle uptake is followed by selective sorting of the constituent apoprotein 
components within the endosome for resecretion, a process known as retro 
endocytosis, whereas the cholesterol component exits the body via biliary 
secretion (239, 286, 287, 338). In polarised hepatocytes SR-BI localises to 
both the sinusoidal (basal) and canaliculur (apical) surfaces; it is thought to 
transcytose between the two in response to cholesterol requirements (53, 
123, 287). Although the precise endocytic pathway employed by SR-BI is 
unknown, its trafficking is thought to be mediated by factors such as 
membrane associated protein 17, which targets SR-BI-HDL complexes to the 
sub apical recycling compartment of the endosomal pathway (286).  A recent 
study suggests that intracellular SR-BI may mediate the trafficking of 
cholesterol between organelles (4). 
 
50 
The ability of SR-BI to strip HDL particles of CE allows the liver to dispose of 
excess cholesterol whilst returning de-lipidated apoproteins into circulation. 
This is the basic principle of reverse cholesterol transport (RCT), whereby 
cholesterol transporters upon peripheral macrophage efflux excess 
cholesterol to HDL particles, which in turn deliver it to the liver for SR-BI 
dependent excretion (319). LDL cannot mediate RCT (260) and thus high LDL 
levels correlate with atherosclerotic lesions caused by cholesterol 
accumulation, whereas high levels of HDL are protective against 
atherosclerosis (2). Although SR-BI can bind VLDL (331) it is not thought to 
donate cholesterol esters in selective uptake (50), and it is unclear whether 
VLDL is endocytosed by SR-BI. Lipoprotein metabolism by SR-BI is 
summarised in Figure 1-4. 
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Figure 1-4 SR-BI-lipoprotein interactions within a hepatocyte. 
(1) HDL binds SR-BI. (2) Selective cholesterol uptake and cholesterol efflux 
occur at the plasma membrane. (3) SR-BI mediated HDL endocytosis. (4) 
Vesicular trafficking to sub-apical recycling compartment – directed via 
PDZK1. (5) Selective sorting of cholesterol for excretion via bile canalicular. 
(6) Recycling of HDL protein component to the plasma membrane (286). 
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Alternative splicing of SR-BI mRNA yields the SR-BII isoform; identical in 
respect to the extracellular ligand binding domain, SR-BII has a unique C-
terminal intracellular region that, importantly, lacks the PDZ domain present in 
SR-BI (330). Whilst the majority of SR-BI is found upon the cell surface, ~85% 
of SR-BII is expressed intracellularly, a reflection of its altered interaction(s) 
with adaptor proteins (89). Indeed PDZK1 KO mice show reduced SR-BI 
expression whilst SR-BII levels remain unaffected (156). Like SR-BI, SR-BII is 
capable of both selective uptake of cholesterol and receptor mediated 
endocytosis. However HDL whole particle uptake occurs much more rapidly 
with SR-BII (89). This was discovered to occur via clathrin coated vesicles, a 
process mediated by a C-terminal dileucine motif; insertion of this motif into 
the C-terminus of SR-BI incurs SR-BII like trafficking (88). Recently, Svensson 
et. al. reported a theoretical third isoform, SR-BIII, although the biological 
significance of this finding is unknown (302). 
 
As the name suggests, scavenger receptors typically have a diverse range of 
ligands. Other SR-BI ligands include modified lipoproteins such as oxidised or 
acetylated LDL, advance glycation end products and serum amyloid A (56, 
103, 115, 235). More recently SR-BI has been reported to recognise 
components of bacterial cell walls (39). Furthermore, expression of SR-BI in 
non-phagocytic cells facilitates the intracellular accumulation of bacteria. This 
suggests a role for SR-BI/II in innate immunity possibly via broad pattern 
recognition abilities (246, 323). 
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In summary the class B scavenger receptors interact with lipoproteins and are 
capable of selective cholesterol uptake and receptor mediated endocytosis, 
making them central to cholesterol metabolism. The way in which these 
ligands are metabolised and trafficked is determined by the environment of 
the surrounding membrane and specific interactions between the scavenger 
receptor C-termini and different adaptor molecules.  
54 
1.7 HCV and lipoproteins. 
Over the last 15 years there has been a steady accumulation of evidence to 
implicate lipoproteins in HCV infection. Initial observations came from infected 
patient sera in the early 1990s, however only with the advent of the HCVcc 
system has the true nature of HCV-lipoprotein association become apparent. 
The following section covers the extraordinary ability of HCV to exploit the 
liver’s central role in lipid metabolism. 
 
Differential centrifugation through a continuous gradient of inert medium, such 
as sucrose, allows the separation of viruses according to their density, which 
is in turn determined by the relative nucleic acid, protein and lipid composition 
of individual virions (102). This technique has been used by virologists for 
over 40 years (230), consequently analysis of HCV by density centrifugation 
was almost inevitable.  As a rule particle density is relatively invariable within 
viral species, for instance Adenovirus particles have a homogenous density of 
~1.34g/ml (55, 102). Therefore it came as some surprise to find that upon 
fractionation of HCV derived from patient sera, RNA genomes could be found 
across a broad range of densities; 1.03-1.20 g/ml (214). A large proportion of 
virions appeared to be of particular low density (~1.08g/ml) suggesting a high 
lipid content, indeed removal of lipids with detergents increased virion density 
to 1.25g/ml (214).  The density heterogeneity and apparent high lipid 
composition of serum HCV particles does not conform to the traditional model 
of an enveloped virion, therefore it was hypothesised that HCV associates 
with host serum components.  
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In 1992 Thomssen et. al. demonstrated that low density HCV particles could 
be precipitated with anti-ApoB-100 antibodies, indicating an association with 
low density lipoproteins (312, 313). However understanding the nature of this 
association would go little further until 2002 when Andre et. al. used electron 
microscopy to study the sera of HCV infected patients (8). They observed low 
density spherical structures of ~100nm, atypical of normal human lipoproteins, 
treatment with detergent revealed central viral capsids that could be 
recognised using HCV core antibodies, they named these structures HCV 
lipo-viro-particles (LVPs) (8).  
 
Subsequent studies using infected patient liver and serum samples revealed 
that LVPs contain HCV RNA and structural proteins, ApoB-100/48, ApoE, 
ApoC, triglyceride, cholesterol and phospholipids (8, 77, 210, 232, 233, 312). 
However, analysis of their lipid composition suggests that they are not merely 
HCV particles carrying surface lipoproteins (8). LVPs have characteristics of 
both lipoproteins and virus particles and are believed to circulate as functional 
carriers of dietary lipids (77). Indeed, HCV LVP are reported to interact with 
the metabolic enzyme lipoprotein lipase, however this is believed to facilitate 
particle entry along a non-permissive pathway (9). 
 
Prior to an in vitro system to measure particle infectivity, observations were 
made using patient sera and Chimpanzees. These early studies suggested 
that low density LVP are more infectious than those of a higher density (45, 
128). Initial experiments to elucidate the mechanism of LVP formation 
measured the association of HCV structural proteins with lipoproteins, 
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although a consensus has not yet been reached. Lambot et. al. used 
immobilised sE2 to capture VLDL and LDL in vitro (164) , Monazahian et. al. 
made similar observations using co-precipitation techniques (219), however 
others have failed to detect a direct interaction (337).  
 
True characterisation of HCV LVPs began with the introduction of cell culture 
proficient JFH-1 HCVcc. Using HCV genome specific RT-PCR to measure 
particle distribution throughout the density gradient, it was observed that, like 
serum virus, HCVcc particles exhibit a broad range of densities. However 
peak HCVcc genome titre occurred at a slightly higher density than serum 
virus (~1.15g/ml), suggesting reduced association with lipoproteins (179, 328). 
The ability to measure infectivity as well as genome titre allows the calculation 
of specific infectivity, i.e. a measure of the infectious potential of any given 
particle. By correlation of density with specific infectivity, it was demonstrated 
that high density particles are less infectious than those of a low density (179), 
consistent with previous observations in the Chimpanzee (45, 128). 
 
A chimeric HCVcc genome containing the structural genes of strain J6 and the 
non-structural genes of JFH-1 (J6/JFH) produces particles in vitro that are 
infectious for Chimpanzees (179, 180). Interestingly, J6/JFH virus recovered 
from the plasma of infected animals displayed a density distribution profile 
more similar to that of patient sera derived HCV than HCVcc, accompanied by 
an increase in specific infectivity. Propagation of Chimpanzee plasma HCV in 
cultured hepatoma cells restored the density distribution and infectivity to that 
of cell culture derived HCV (180). Taken together these data suggest that 
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lipoprotein association promotes HCV infectivity and in vitro HCVcc particles 
do not fully represent patient serum derived LVPs. 
 
1.7.1 Assembly and release. 
Prior to the development cell culture proficient HCV the assembly and release 
of infectious particles had been somewhat of a “black box”. We knew of the 
components entering the process, yet the mechanisms of HCV particle egress 
remained mysterious. However, publications in the last 12 months have 
revealed that HCV commandeers the hepatic VLDL assembly machinery to 
produce infectious LVP. 
 
As covered earlier, the process of VLDL assembly and release is relatively 
well understood and this information was utilised to investigate HCV 
production by infected hepatoma cell lines. Intracellular infectious HCV 
particles are of a higher density than secreted particles, suggesting that low 
density is gained during viral egress (110). Treatment of infected cells with 
brefeldin, a broad range inhibitor of the secretory pathway, reduced particle 
release and led to an accumulation of intracellular virus (109).  Inhibition of 
VLDL assembly using MTP inhibitors or silencing of apoproteins apoB-100 
and apoE, prevented both the release of particles and brefeldin induced 
intracellular accumulation, indicating a block to virion assembly. However 
these treatments had no effect on viral RNA replication or intracellular 
genome concentrations (63, 109, 131, 224).  
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These data point to a requirement for the VLDL assembly machinery for the 
packaging of viral RNA and structural proteins into infectious HCV LVP, which 
are trafficked via the secretory pathway to allow particle release. Intracellular 
particles are vulnerable to pre-secretory degradation (109), suggesting that an 
infected host cell treats HCV LVPs as VLDLs, targeting lipid poor forms for 
recycling in the absence of sufficient substrate(s).  
 
It is not yet clear how the virus structural proteins and host apoproteins 
associate during particle assembly. However current data suggests that lipid 
droplets (LD), intracellular organelles responsible for lipid storage, are central 
to this process. HCV genome replication is believed to occur on membranes 
in and around the endoplasmic reticulum, mature E1E2 heterodimers also 
reside there (181, 220). Core protein, however, translocates to the LDs and is 
seen to coat their surface (41, 42, 215), NS5A also localises with the LDs 
(280), viral protein association with LDs is essential for the production of 
infectious particles. Core directs the redistribution of LDs along the micro-
tubule network bringing them into the vicinity of membranes bearing genome 
replication complexes (41). It is currently believed that assembly occurs at 
these juxtapositions (41, 215), indeed numerous studies have demonstrated a 
accumulation of viral proteins and RNA at these sites (131, 189, 215, 305). 
Furthermore, LDs provide a source of triglycerides for the loading of lipids on 
to ApoB (321), suggesting that the VLDL and HCV assembly pathways 
converge at this location. (Figure 1-5). 
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Figure 1-5 Lipo-viro-particle assembly. 
Newly synthesised ApoB is loaded with lipid by MTP in the rough ER, yielding 
a VLDL precursor. Upon translocation of the precursor to the ER lumen MTP 
mediated lipidation continues, with the lipid droplets providing the major 
source of triglycerides and cholesterol. Within an infected liver, these ER 
membranes are also the site of HCV RNA replication and it is believed particle 
assembly occurs in parallel with VLDL, allowing virions to become 
incorporated into lipo-viro-particles. Image taken from Ye et. al. (343) 
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1.7.2 Low density lipoprotein receptor and virus entry. 
Several reports provide evidence that LDLR may be an additional candidate 
receptor for HCV attachment and entry, notably, these studies were carried 
out almost exclusively with patient serum derived virus. Low density serum 
HCV will bind to cells expressing LDLR, whereas higher density particles do 
not (218, 336). This interaction is inhibited by the addition of native LDL, 
alternatively removal of cell associated LDL enhances HCV binding (95, 218, 
336), these data suggest that HCV interacts with LDLR in an analogous 
manner to its natural ligand. A recent study by Molina et. al. demonstrated  
that  infection of primary human hepatocytes by serum HCV is inhibited by 
anti-LDLR mAbs and recombinant soluble LDLR peptides, furthermore, 
treatments to modulate LDLR expression similarly affected HCV infection 
(216). However, the above observations have yet to be recapitulated using 
the HCVcc/pp systems (24), thus limiting our understanding of HCV-LDLR 
interactions. Current data suggest that envelope proteins do not interact with 
LDLR directly (24, 336) and that HCV relies on associated lipoproteins for 
binding (219, 337), it is likely that HCVcc/pp are not sufficiently lipoprotein-like 
for this to occur. 
 
As illustrated by investigations on the role of LDLR in HCV entry, in vitro 
generated HCVcc may not represent native HCV circulating within an infected 
individual. Cultured human hepatoma cells often have restrictions in their 
ability to assemble lipid rich VLDL particles (316), this would almost certainly 
impact on the nature of secreted HCV LVP. Moreover, circulating lipoproteins 
undergo continual modification in response to metabolic requirements (321). 
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In vitro culture medium, into which HCVcc LVPs are secreted, would not 
replicate this environment. Therefore, understanding how to better replicate 
these systems without the use of animal models is imperative.  
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1.8 Project Objectives. 
The aim of this study was to investigate the role of SR-BI in HCV attachment 
and entry, using recombinant soluble HCV glycoproteins and the HCVcc/pp 
infectious models. In doing this, we also hoped to examine the importance of 
lipoproteins in HCV infection. The broad objective of the Birmingham HCV 
Research Group is to characterise the routes of transmission exhibited by 
HCV, specifically focussing on the interplay between virus particles and 
cellular receptors. 
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2 Materials and methods. 
2.1 Cell lines. 
Table 2-1 details the different cell lines used in this study. Cells were 
maintained in tissue culture flasks (Becton Dickinson, NJ, USA) in the stated 
culture media supplemented with 10% foetal calf serum (FCS) (Gibco, 
CA,USA), 1% non-essential amino acids (Gibco), 1% L-glutamine (Gibco) and 
50units/ml penicillin and 50µg/ml streptomycin (P/S) (Gibco). 
 
 
Table 2-1 List of cell lines. 
 
2.2 Antibodies. 
Table 2-2 details the antibodies used in this study. 
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Table 2-2 List of antibodies. 
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Preparation of rat anti-E2 mAbs. 
Anti-E2 and control mAbs were cloned from rats immunised with recombinant 
antigen as previously described (99, 130, 282). Hybridoma cells expressing 
the panel of antibodies were grown in miniPERM bioreactors (Greiner Bio 
One, Germany), according to the manufacturers instructions, under the 
supervision of Dr. Margaret Goodall. Approximately 250ml of cell culture 
medium containing mAb was harvested from each bioreactor allowing IgG 
isolation using the following protocol. 
 
1. A 2ml column containing 750µl of Fast-flow protein G conjugated 
sepharose beads (GE Healthcare, UK) was prepared for each mAb to 
be isolated.  
2. To capture IgG, the column was connected to a peristaltic pump 
(Pharmacia, Sweden) and 10ml phosphate buffered saline (PBS) 
(Gibco) passed through to wash, followed by 10ml of harvested culture 
media. 
3. The column was washed once more and the IgG eluted with 10ml 0.1M 
glycine (Sigma-Aldrich, MO, USA) at pH 2.7, the acidic eluate was 
immediately neutralised with 650µl 1M TRIS (Sigma-Aldrich) at pH 9.0.  
4. Finally, the eluate was dialysed against PBS overnight at 4ºC. IgG 
concentration was determined using a UV spectrophotometer 
(Amersham, UK).  
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Isolation of patient IgG. 
The sera of patients infected with HCV was kindly provided by Dr. David 
Mutimer and Dr. David Adams of the Queen Elizabeth Hospital Liver Unit. 
Prior to isolation of IgG sera was heat inactivated by treatment at 60ºC for 1.5 
hrs. IgG was isolated using a 5ml column containing 2.5ml Fast-flow beads 
following the above protocol. Remaining patient sera was stored in a secure 
biological hazard container at -80ºC. 
2.3 Plasmids and proteins. 
 
Table 2-3 and Table 2-4 detail the plasmids and recombinant proteins used in 
this study. 
 
Table 2-3 List of plasmids. 
 
Table 2-4 List of recombinant proteins. 
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2.4 Basic techniques. 
 
Flow cytometry. 
1. Cells of interest were trypsinised (Gibco) for 5 mins, resuspended in 
appropriate media and counted using a haemocytometer. Cells were 
then pelleted in a 5804R centrifuge (Eppendorf, Germany) at 1500rpm 
for 5 mins and diluted to 2x106 cells/ml in PBS + 0.5% bovine serum 
albumin (BSA) (Sigma-Aldrich). 
2. If cells required fixation prior to staining they were treated for 5 mins 
with 3% paraformaldehyde (PFA) (TAAB, UK), followed by a PBS wash 
and resuspension in PBS + 0.5% BSA. If permeablisation was 
necessary, fixed cell were resuspended in PBS + 0.5% BSA + 0.5% 
saponin (Sigma-Aldrich) and all subsequent steps carried out in this 
buffer. 
3. Suspended cells were incubated for 20 mins at RT to block. If using 
saponin this also served as a permablisation step. 
4. Antibody staining was performed in a 96 well U bottomed plate 
(Corning, NY, USA) with 2x105 cells/well. 100$l of cell suspension was 
put into each well, the cells were pelleted by centrifugation at 1500rpm 
for 5 mins and then resuspended in 70-100ul of primary antibody or 
control diluted in PBS + 0.5% BSA  (+ 0.01% saponin).  
5. After 45 mins incubation at RT, cells were washed with PBS; 100$l 
PBS was added to each well and the cells were pelleted by 
centrifugation. This process was repeated after which the cells were 
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resuspended in 70-100ul of fluorescently conjugated secondary 
antibody diluted as above. 
6. A further 45 mins incubation completed the antibody staining and the 
cells were washed in PBS as above. In the case of live staining, the 
cells were fixed, as in step 2, prior to analysis. 
7. Staining intensities were measured using a Facscalibur flow cytometer 
(Becton Dickinson), the data was captured with Cell Quest (Becton 
Dickinson) and analysed using  FlowJo (Tree Star, OR, USA). 
 
Indirect immunofluorescence.  
1. Cells of interest were seeded at 3x104 cells/100mm2 in 48, 24 or 12 
well tissue culture plates (Becton Dickinson) 24hrs prior to study.  
2. Cells were fixed prior to staining by 5 mins incubation with ice cold 
methanol (Fisher Scientific, UK), after which the cells were blocked for 
20 mins with either PBS + 0.5% BSA or, if permeablising, PBS + 0.5% 
BSA + 0.01% saponin. 
3. Primary antibody staining was achieved by incubation for 45 mins at 
RT with antibody or control diluted in the appropriate buffer. 
4. To wash the cells, diluted antibody was removed by careful aspiration, 
followed by the addition of excess PBS, the process was then 
repeated. 
5. Secondary antibody staining was achieved by incubation for 45 mins at 
RT with fluorescently conjugated secondary antibody diluted in the 
appropriate buffer. 
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6. Finally, the cells were washed as in step 4 and the staining visualised 
using a fluorescent microscope (Nikon TE2000, Japan). Images were 
taken using a digital camera (Hammatsu, Japan). 
 
Enzyme linked immunosorbent assay (ELISA). 
1. Immulon 2HB flat bottom assay plates (Thermo, MA, USA) were first 
coated with a capture agent of either Galanthus nivalis (GNA) lectin 
(5$g/ml) (Sigma-Aldrich) or recombinant CD81 LEL (5$g/ml). 50-100$l 
of capture agent diluted in PBS was added to each well followed by an 
overnight (O/N) incubation at 4°C. The GNA and CD81 capture ELISAs 
have been previously described (84, 99). 
2. The plate was washed 3 times by the addition of excess PBS after 
which it was blocked for 30 mins at RT with PBS + 5% BSA. 
3. The plate was then incubated with 50$l/well soluble HCV E2 
glycoprotein diluted in PBS + 5% BSA (0.5-1$g/ml) for 4 hrs at 37°C. 
Wells incubated with buffer alone served as a negative control. 
4. The plate was washed as in step 2 and incubated with 50$l/well anti-E2 
or control antibody diluted in PBS + 5% BSA (5$g/ml, or as stated in 
figure) for 45 mins at RT. 
5. Bound antibody was detected using 50$l/well HRP conjugated donkey 
anti-rat IgG secondary diluted in PBS + 5% BSA (1/1000) for 45 mins 
at RT.  
6. Binding was realised by addition of 50$l/well HRP substrate (BioFix, 
MD, USA), HCl stop solution (BioFX) being used once the signal had 
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developed. The absorbance of each well was measured at 450nm 
using a plate reader (Thermo) and associated Ascent software. 
 
Cell based soluble E2 binding assay. 
1. A flow cytometry based assay was used to assess sE2 binding to cells. 
Trypsinised cells were resuspended at 2x106 cells/ml in PBS + 0.5% 
BSA + 0.01% sodium azide (Sigma) and incubated at RT for 20 mins. 
Sodium azide inhibits cell metabolism and therefore ensures minimal 
trafficking of proteins to and from the cell membrane. 
2. As detailed in the flow cytometry protocol, sE2 binding was carried out 
in a 96 well U bottomed plate. Cells were resuspended in 70-100$l of 
sE2 diluted in the above buffer and incubated for 1 hr at 37°C. 
3. Cells were PBS washed as in the flow cytometry protocol, 
resuspended in rat anti-E2 mAb diluted in above buffer (5$g/ml, or as 
stated in figure) and incubated for 45 mins at RT. 
4. Cells were washed and bound E2-Ab complexes detected using goat 
anti-rat IgG fluorescently conjugated secondary antibody diluted buffer 
(1/1000) and incubated for 45 mins at RT. 
5. Finally, cells were washed and fixed and analysed as detailed in the 
flow cytometry protocol. This protocol was first developed by Flint and 
co-workers (98, 99). 
 
Transfections. 
1. Transfections were carried out using the Fugene (Roche, 
Switzerland), Lipofectamine (Invitrogen, CA, USA) or Profection 
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(Promega, WI, USA) kits according to the manufacturer’s guidelines. 
Briefly, cells were seeded at 800 cells/mm2 in P/S free media 24hrs 
prior to transfection. 
2. Transfections were carried out at 37°C for 8hrs, using ~1$g of plasmid 
DNA per 2x105 cells, after which the transfection mixture was 
replaced with DMEM + 3% FCS + P/S. 
3. Expression efficiency was typically monitored 48 hrs post transfection. 
 
TRIP retrovirus gene delivery system. 
The TRIP system is a retrovirus gene expression vector developed by Zennou 
et. al. (347). It produces virus vector particles, formed around a replication 
deficient HIV gag-pol core, that bear the envelope glycoprotein of vesicular 
stomatitis virus (VSVG). These particles can package a gene of interest as an 
RNA transcript, subsequent transduction of a cell line with the TRIP system 
results in reverse transcription of the target gene and its insertion into the 
genomic DNA. In this study transduced cells were not under selection, 
however they maintained exogenous gene expression for around 1 month, 
after which they were discarded. The following protocol documents the 
synthesis and use of TRIP particles, the cloning of SR-BII for use in the TRIP 
system is detailed later. 
 
1. TRIP particles were produced by Fugene transfection of 293T cells with 
the following quantities of plasmids encoding the constituent elements; 
400ng VSVG envelope, 600ng TRIP gag-pol and 600ng target gene. 
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Cells were transfected in 6 well tissue culture plates for 8hrs, after 
which the culture media was changed to DMEM + 3% FCS + P/S. 
2. Transfection efficiency was monitored by the inclusion of a TRIP 
plasmid encoding enhanced green fluorescent protein as a target gene 
(TRIP EGFP). 
3. Culture media containing TRIP particles was harvested at 48 and 72 
hrs post transfection and passed through a 0.2$M filter to remove any 
contaminating 293T cells. Transduction of target cells was performed 
immediately. 
4. Target cells were seeded at 4x105 cells/well in a 6 well tissue culture 
plate 24 hrs prior to transduction. To transduce, cells were incubated 
O/N with harvested TRIP culture media diluted 1:1 in DMEM + 3% FCS 
+ P/S. After which the media was changed to DMEM + 10% FCS + 
P/S. 
5. Transduction efficiency was assessed after 48 hrs by monitoring 
expression of TRIP EGFP and flow cytometric detection of target 
gene(s). 
 
HCV pseudo particle system. 
The HCVpp system used in this study is similar to that described by Hsu et. al 
and Pohlmann et. al. (130, 250). Like the TRIP system, HCVpp are based 
around a replication deficient HIV gag-pol core but carry the E1E2 
glycoproteins of HCV. Infection is detected by an EGFP reporter gene 
packaged into the HCVpp. As the particles do not encode any HCV structural 
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proteins and are incapable of further rounds of replication they only mimic the 
entry process of HCV. 
 
1. HCVpp were synthesised in a similar manner to TRIP particles. Briefly, 
293T cells were Fugene transfected with plasmids encoding HCV E1E2 
(1$g), HIV gag-pol (250ng) and an EGFP reporter (250ng). 
2. Culture media containing HCVpp was harvested at 48 and 72 hrs post 
transfection. Infection of target cells was performed immediately. 
3. Target cells were seeded at 6x104 cells/well in a 12 well tissue culture 
plate 24 hrs prior to infection. To infect, cells were incubated for 8 hrs 
with harvested HCVpp culture media diluted 1:3 in DMEM + 3% FCS + 
P/S. After which the media was refreshed. 
4. Infection was assessed after 72 hrs by flow cytometric detection of the 
EGFP reporter. 
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2.5 Cell culture proficient hepatitis C virus. 
 
The following section details the synthesis and use of HCVcc particles. 
Currently, all HCVcc viruses are constructed around the non-structural 
proteins of HCV strain JFH-1, a unique isolate capable of producing particles 
in certain hepatoma cell lines (179, 328, 351). The HCVcc viruses used in this 
study were JFH-1 wild type, cell culture adapted JFH-1 G451R, and a 
chimeric J6/JFH virus which encodes core, E1, E2, p7 and NS2 of strain J6 
HCV (179, 328, 352). In each case virus was produced by transcription of 
RNA from a plasmid encoding the HCV genome, introduction of RNA 
genomes into Huh-7.5 cells by electroporation and subsequent harvest of 
secreted HCVcc particles. 
 
RNA synthesis. 
1. RNA transcripts of the HCV genome were produced using the T7 RNA 
polymerase kit (Ambion, TX, USA) according to the manufacturer’s 
instructions. Briefly, 5$g of plasmid containing a cDNA clone of the 
HCV genome was linearised by XbaI digest (Promega).  
2. 1$g of linearised plasmid was used as a template for RNA 
transcription, the reaction mixture was incubated at 37°C for 3-4 hrs, 
after which the RNA was cleaned up using the RNeasy MinElute kit 
(Qiagen, Netherlands) according to manufacturer’s instructions. 
3. The quality of the RNA was assessed by gel electrophoresis on a 1% 
agarose gel (Bioline, UK). Typical yields, as measured by a UV 
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spectrophotometer (Amersham), were 250-1000ng/$l. A gel image 
showing HCV RNA transcripts is displayed in Figure 2-1. 
 
 
Figure 2-1 In vitro transcribed HCV RNA. 
Realised on a 1% agarose gel. 
 
Electroporation. 
1. Huh-7.5 cells at 60-80% confluence were trypsinised, resuspended in 
DMEM and counted.  
2. To prepare, the cells were washed with excess ice cold PBS and 
pelleted by centrifugation at 1250rpm for 5 mins at 1°C, this process 
was repeated after which the cells were resuspended in ice cold PBS 
at 1.5x107 cells/ml and placed on ice. 
3. To electroporate, 400$l of cell suspension was mixed with 3$g of 
genomic RNA and transferred into a 0.2cm EP cuvette (Sigma-Aldrich). 
EPs were carried out at 780v in an Electro Square Porator (Harvard 
Apparatus, MA, USA). 
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4. After EP the cells were allowed to stand for 5 mins at RT prior to being 
transferred into 10ml of pre-warmed DMEM + 10% FCS + P/S. 8ml of 
the resuspended cells were placed in a T75 culture flask, and the 
remainder put into 2 wells of a 24 well tissue culture plate to allow the 
monitoring of HCV protein expression. The cells were immediately 
taken into category 3 containment laboratories for culture and harvest 
of particles. 
5. At 48 hrs post EP, the efficiency of viral replication was quantified by 
detection of the HCV non-structural protein NS5A. Briefly, 
electroporated cells were stained using the immunofluorescence (IF) 
protocol with saponin permeablisation (as detailed above), mouse anti-
NS5A mAb 9E10 was used at 1/200 dilution. JFH infected NS5A 
positive Huh-7.5 cells are shown in Figure 2-2. 
6. HCVcc particles were harvested between 4 and 14 days post EP, after 
which the cells were discarded. To harvest, infected cells were cultured 
in a minimal volume of DMEM + 3% FCS  + P/S and media containing 
secreted virions collected every 8-14 hrs. Harvested virus was frozen 
prior to titration using the infection assay. 
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Figure 2-2 Electroporated Huh-7.5 cells. 
Huh-7.5 cells 48 hrs post EP with JFH-1 RNA, infection was detected by 
visualisation of HCV NS5A. 
 
Infection assay. 
All HCVcc infectivity data presented in this thesis was obtained using the 
following protocol. 
1. Naïve Huh-7.5 cells were seeded at 1.5x104 cells/well in 48 well tissue 
culture plate 24 hrs prior to infection.  
2. To infect, the media was removed from the cells and replaced with 
100$l of HCVcc virus diluted in DMEM + 3% FCS + P/S. 
3. After 8 hrs at 37°C the HCVcc inoculum was removed and the cells 
refed with 150$l of DMEM + 3% FCS + P/S, infections were allowed to 
proceed for 48 or 72 hrs, as stated in the figure legends. 
4. Infected cells were fixed and NS5A positive cells detected using the IF 
protocol as stated above. 
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5. The level of infection was assessed by enumeration of NS5A positive 
cells using a fluorescence microscope, data is expressed as infectious 
units (IU) per ml of harvested HCVcc culture media; 1 infected cell = 1 
IU. To ensure reliable data read outs, HCVcc virus was always diluted 
according to harvest titre so that each well contained 150-300IU.  
 
Neutralisation assay. 
Much of the work covered in this thesis regards the use of antibodies or 
receptor mimics to inhibit HCVcc infection. These treatments were evaluated 
using an adapted form of the infection assay. 
1. Huh-7.5 cells were seeded for infection, as above. 
2. To treat virus particles, titrated HCVcc were diluted in DMEM + 3% 
FCS + P/S containing the appropriate concentration of inhibitory or 
control compound. Alternatively, to treat target Huh-7.5 cells, culture 
media was replaced by 80$l of DMEM + 3% FCS + P/S containing the 
inhibitory or control compound. In either case pre-treatment was for 1 
hr at 37°C. 
3. To infect, pre-treated virus was used to inoculate naïve Huh-7.5 cells. If 
pre-treating target cells, 80$l of appropriately diluted HCVcc was added 
directly to the culture media containing the treatment. 
4. In each case the infection was allowed to proceed for 48 hrs. The 
original virus inoculum and inhibitory treatment were present for the 
duration of the assay to ensure evaluation of absolute neutralisation 
titres. 
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5. Data is expressed as percentage neutralisation; this was calculated by 
comparison of the level of infection after inhibitory treatment to that 
after treatment with a control compound. 
 
Statistical analysis of infectivity data. 
To ensure appropriate statistical analysis of infection assays we used a 
D'Agostino & Pearson omnibus normality test to determine whether typical 
infectivity data fits a Gaussian distribution. Briefly, the data from n=10 JFH-1 
and J6/JFH-1 HCVcc infection assays were analysed using GraphPad Prism 
(GraphPad Software, CA, USA), both data sets were deemed to be normally 
distributed as summarised in Table 2-5. We therefore have assumed normal 
distribution for all infectivity data and statistical analyses were performed 
using an unpaired t-test. 
 
 
 
 
Table 2-5 Normality testing. 
Analysis of JFH-1 and J6/JFH-1 infectivity data with the D'Agostino & Pearson 
omnibus normality test following the guidelines in the GraphPad statistics 
handbook. 
 
Iodixanol density gradient centrifugation. 
The analysis of HCVcc particle density was achieved by iodixanol density 
gradient centrifugation. This work was carried out in collaboration with Dr 
Søren Nielsen of Newcastle University Medical School. The preparation and 
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use of the iodixanol gradient columns was performed by Dr Nielsen, the 
remaining work was carried out in Birmingham. 
1. 50ml of culture medium containing harvested HCVcc particles was 
concentrated to 1ml in a Vivaspin 20 column with a 100kDa molecular 
weight cut off (Sartorius, Germany). 
2. Linear iodixanol (Axis-Shield, UK) gradients were prepared using a 
two-chamber gradient maker (Jencons, UK) with light (6%) and dense 
(56%) iodixanol solutions (233). Gradients were used immediately after 
preparation and 0.4 ml of concentrated virus loaded onto each 
gradient.  
3. Samples were centrifuged at 100,000xg for 21h at 4ºC in a L80-M 
ultracentrifuge (Beckman, UK), fractions were harvested and their 
density determined with a digital refractometer (Atago, Japan). 
4. RNA was extracted from each faction using an RNEasy Mini kit 
(Qiagen) according to the manufacturer’s instructions, allowing the 
analysis of HCV genome distribution throughout the density gradient. 
5. HCVcc infectivity within each fraction was determined with a standard 
infection assay. 
 
Quantitative RT-PCR 
Genome copy number within each iodixanol density fraction was measured by 
quantitative RT-PCR, using a Cells Direct kit (Invitrogen) according to the 
manufacturer’s instructions. In summary. 
1. The Cells Direct reaction mixture was made with HCV specific primers 
(PrimerDesign, UK) and GAPDH house keeping gene control primers 
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(Invitrogen). The samples to be tested were derived from cell culture 
media and not cell lysate and do not contain GADPH mRNA, therefore 
0.25µg of HeLa cell RNA (Invitrogen) was added to the mix as a 
template for the GAPDH control primers. 
2. The RT-PCR was carried out in a MicroAmp 96 well optical reaction 
plate (Applied Biosystems, CA, USA), with samples tested in 
quadruplicate. A standard curve was made up with in vitro transcribed 
HCV RNA of known copy number.  
3. The reaction was performed in a MX3000P quantitative PCR machine 
(Stratagene, CA, USA) and the data analysed using the associated 
MXpro software. 
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2.6 Cloning of TRIP SR-BII. 
 
As previously described the TRIP gene vector system can package a target 
gene for delivery to cultured cells. To create TRIP particles containing a 
particular gene it is necessary to clone it into a compatible plasmid 
background. A TRIP plasmid construct must encode an RNA transcript 
comprised of i) an appropriate promoter, ii) the target gene and iii) a lentiviral 
packaging signal that drives the transcript’s inclusion into budding TRIP 
particles.  
 
Cloning of TRIP SR-BII was achieved by restriction enzyme excision from a 
PCDNA3.1 plasmid encoding a fully sequenced human SR-BII cDNA 
(provided by Dr Jim Owen at University College London). The excised gene 
was then transfer cloned into an in-house TRIP plasmid, pJZ189, which 
encodes a packaging signal and a CMV promoter with a downstream 
polylinker (Figure 2-2). 
 
 Figure 2-2 Basic plasmid map 
of pJZ189.  
Position of promoter, packaging 
signal and polylinker are shown. 
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1. The SR-BII coding region was excised from the PCDNA3.1 background 
using the 3’ and 5’ flanking SpeI sites highlighted in Figure 2-2 . 
  
Figure 2-2 Restriction Map. 
Restriction map of SR-BII coding 
sequence, the flanking SpeI sites are 
highlighted in red. 
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2. The digested DNA was ran on a 2% agarose gel allowing gel 
purification of the coding sequence using a MinElute gel extraction kit 
(Qiagen), the excised fragment is shown in Figure 2-2. 
3. TRIP pJZ189 was linearised via the XbaI site found within the 
polylinker (Figure 2-2), creating ends compatible for transfer cloning of 
the SR-BII coding sequence. The ligation products were then used to 
transform omniMAX E.coli (Invitrogen). 
4. As the excised SR-BII sequence had symmetrical 5’ and 3’ SpeI sites 
the fragments will have inserted into pJZ189 in both sense and anti-
sense orientations. Therefore, clones carrying the correctly orientated 
open reading frame (ORF) were identified by PCR screening using a 
forward primer specific to a pJZ189 sequence upstream of the insert 
and a reverse primer specific to a sequence within the SR-BII insert.  
5. Exogenous SR-BII expression efficiency from the selected clones was 
assessed by transduction of CHO cells with TRIP SR-BII particles, this 
is documented in section 3. 
 
 
 
Figure 2-2 SR-BII restriction digest. 
PCDNA3.1 SR-BI (A) and PCDNA3.1 
SR-BII (B) were digested with SpeI, the 
excised SR-BII coding sequence is 
shown at ~1500bp in lane B. 
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2.7 Cloning and synthesis of JFH-1 wt and G451R soluble E2. 
Many early studies into HCV attachment and entry were performed using 
truncated soluble forms of the E2 glycoprotein (99, 100). These recombinant 
proteins contain amino acids 384-661 of the HCV polyprotein, a region 
encompassing all of E2 with the exception of the trans-membrane domain, 
thus rendering the proteins soluble (99, 100). Our study required the direct 
examination of JFH-1 wt and G451R glycoprotein–receptor interactions, to 
achieve this it was necessary to engineer plasmids encoding sE2 for each 
virus.  
 
Our cloning strategy used an existing PCDNA3.1 plasmid that encodes a 
strain H sE2 downstream of a tissue plasminogen activator (tpa) leader 
sequence. When introduced into 293T cells, the tpa leader directs the 
secretion of synthesised sE2 into the culture media and is therefore an 
essential element of the construct. By insertion of a silent and unique 
restriction site at the interface between the tpa leader and sE2 ORF we were 
able to excise the strain H sE2 sequence and transfer clone JFH-1 sE2 PCR 
products into the plasmid background. We also introduced a C-terminal 
epitope tag to the JFH-1 sE2s via an extended reverse primer. This work was 
carried out partly by Dr Peter Balfe.  
 
1. A QuikChange II (Stratagene) site directed mutagenesis kit was used 
to insert a synonymous mutation in the strain H sE2 plasmid at the 3’ 
end of the tpa leader sequence. This alteration created a unique SacII 
restriction site directly upstream of the H sE2 coding sequence, which 
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along with a flanking HindIII site was used to excise the strain H sE2 
ORF, leaving a linearised PCDNA3.1 + tpa leader background (Figure 
2-3). Figure 2-4 displays a gel image of the digested PCDNA3.1 H sE2 
plasmid. 
 
Figure 2-3  Basic plasmid map of PCDNA3.1 H E2. 
The position of the flanking SacII and HindIII sites are shown. 
 
 
 
 
Figure 2-4 PCDNA3.1 H E2 digest. 
Digested with SacII and HindIII to release the ~900bp H sE2 coding 
sequence.  
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The sequence encoding amino acids 384-661 of the HCV polyprotein was 
PCR amplified from plasmids encoding cDNA copies of the JFH-1 wt and 
G451R genomes, using the following primers (Invitrogen); 
 
Forward       
5’AGCCGCGGAGCCAGATCCGGCACCACCACCGTTGGAGGCG3’  
 
Reverse 
5’GACAGGGACAGGTCCGAGAGTACTAGTATCCGCGGCAAGGTACAGTG
AAAGCTTAAGCGCG3’ (sequence shown is the reverse complement) 
 
The sections of red text are HCV specific sequences, the bold text indicate the 
5’ SacII and 3’ HindIII sites necessary for transfer cloning, the underlined 
sequence encodes a HIV gp120 epitope tag (STSIRGKVQ) recognised by 
mAb 10/76B. Figure 2-5 displays the ~900bp PCR product amplified from 
JFH-1 wt and G451R plasmids.  
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Figure 2-5 sE2 coding region PCR. 
JFH-1 (A) and JFH-1 G451R (B) PCR products encoding amino acids 
384-661 of the HCV polyprotein. 
 
2. The PCR products were gel purified and ligated into the pGEM-T easy 
plasmid background (Promega) to allowing transformation of E.coli. 
3. Clones carrying the correct insert were identified by PCR screening 
using a pGEM-T easy specific forward primer and HCV specific reverse 
primer. The selected clones were sequenced and subsequently 
digested with SacII and HindIII for transfer into the PCDNA3.1 + tpa 
leader background.  
4. Candidates recovered from the transfer cloning were PCR screened  
and sequenced once more prior to evaluating their protein expression. 
Figure 2-6 displays a sample of the sequencing data obtained; the 
G451R point mutation is highlighted. 
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Figure 2-6 sE2 sequencing. 
JFH-1 and JFH-1 G451R sE2 sequencing data was compared to a 
reference JFH-1 E2 sequence (accession number AB047639) using 
the CLC Workbench software (CLCBio, Denmark). The G451R point 
mutation is highlighted.  
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5. To investigate whether the selected clones produced sE2, flasks of 
293T cells were transfected with 10$g of each plasmid using the 
Profection kit (as documented earlier). Supernatant containing 
secreted protein was harvested at 48 hrs post transfection.  
6. Supernatants were tested using a GNA capture ELISA (as documented 
earlier). Figure 2-7 displays the detection of recombinant JFH-1 wt and 
G451R sE2 by anti-E2 mAb 3/11 and anti-tag mAb 10/76B, untagged 
strain H sE2 was used as a control. 
 
Figure 2-7 Expression of sE2. 
JFH-1 (red line), JFH-1 G451R (blue) and untagged strain H (black) 
sE2s were immobilised in an ELISA plate by GNA capture. Bound 
glycoprotein was detected with 1µg/ml anti E2 mAb 3/11 (A) or anti-tag 
mAb 10/76B (B). Error bars indicate standard deviation from the mean 
n=3. 
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7. Large scale transfections were carried out to produce sufficient sE2 for 
investigation of glycoprotein-receptor interactions. The involvement of 
lipoproteins was eliminated by culturing the transfected 293T cells in 
media containing de-lipidated FBS, supplied by Dr Søren Nielsen of 
Newcastle University.  
8. 50ml of harvested supernatant containing JFH-1 wt and G451R sE2 
was concentrated to 2.5ml using Vivaspin 20 columns with a 10kDa 
molecular weight cut off (Sartorius). The relative concentration of each 
preparation was assessed by GNA capture ELISA using the anti-tag 
mAb 10/76B, Figure 2-8 details the calculation of either glycoprotein’s 
concentration, expressed as relative OD units. 
9. We assessed sE2-receptor interactions using the cell based E2 binding 
assay and CD81 capture ELISA (both documented earlier), in each 
case protein concentrations were matched by appropriate dilution. 
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Figure 2-8 Titration of sE2. 
Serial dilutions of JFH-1 (A) and JFH-1 G451R (B) sE2 were captured 
in a GNA ELISA, bound glycoprotein was detected with 1µg/ml anti-tag 
mAb 10/76B. The relative concentration of each sE2 was assessed by 
calculation of OD units; three readings were taken from a linear section 
of each curve (at 1/750,1250 and 1750). OD units were calculated by 
multiplying the absorbance by the reciprocal dilution for each reading. 
Comparison of  the mean OD units for either glycoprotein suggests that 
JFH-1 sE2 is ~8% more concentrated than JFH-1 G451R sE2, 
therefore JFH-1 sE2 was diluted appropriately before use in the assays 
presented in the results section.  
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3 Results: Investigations using CHO cell expressed SR-BI. 
The work documented in this thesis is reliant on a number of techniques and 
reagents, this chapter covers the validation of these tools along with studies 
using a panel of SR-BI mutants and the splice variant SR-BII. 
  
3.1 Expression of SR-BI in CHO cells. 
To investigate the interaction of HCV glycoproteins with SR-BI it was 
necessary to identify a cell background lacking functioning viral receptors. 
Hamster derived CHO cells do not bind HCV sE2 (274) and it has been shown 
that SR-BI expressed in a CHO cell is functional with regards to lipid uptake 
and trafficking (239, 259, 349). We therefore began work with a CHO cell line 
stably expressing human SR-BI. We assessed SR-BI expression in CHO cells 
using a panel of anti-SR-BI antibodies by flow cytometry and 
immunofluorescent microscopy (Figure 3-1). Figure 3-1 A-C show live cell 
staining of CHO-SRBI and represent plasma membrane SR-BI expression. 
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Figure 3-1 Expression of SR-BI on CHO cells.  
CHO cells (filled histogram) or those stably expressing human SR-BI (unfilled 
histogram) were analysed by flow cytometry after live cell surface staining 
using 1/500 rabbit anti-SR-BI sera (A.), 1$g/ml mouse anti-SR-BI mAb 3D5 
(B.) or 1$g/ml human anti-SR-BI mAb C11 (C.). Methanol fixed parental CHO 
(D.) or those expressing SR-BI (E.) were stained using 1$g/ml mAb anti-Cla1 
(SR-BI). The images were taken at X200 magnification, scale bars represent 
20$m. 
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3.2 CHO cells expressing human SR-BI bind soluble HCV E2 
glycoprotein. 
Previous studies have established an interaction between soluble HCV E2 
and human SR-BI (274), we aimed to recapitulate these findings in our CHO-
SR-BI background. Flint et. al. demonstrated limited availability of epitopes on 
sE2 when bound to CD81 (99), we were interested to identify the epitopes 
exposed on envelope protein when bound to SR-BI. Eight anti-E2 mAbs 
specific for non-overlapping epitopes between residues 384-551 of the HCV 
polyprotein were prepared as documented in section 2. Immunoglobulins 
isolated from these supernatants were assessed for their reactivity with 
immobilised strain HCV-1 sE2 by ELISA (Figure 3-2). All of the mAbs bound 
sE2 and demonstrated a range of relative binding affinities. To investigate the 
availability of mAb epitopes on E2 bound to SR-BI, CHO-SR-BI cells were 
incubated with sE2 and the bound protein detected with the mAbs by flow 
cytometry (Figure 3-3). Recombinant HCV glycoprotein did not bind to 
parental CHO cells (Figure 3-4) Most of the mAbs were able to detect cell 
bound E2, however mAb 9/75 recognised sE2 with the highest fluorescence. 
mAb 9/75 is specific for residues 524-531 of E2 (130), a region reported to be 
involved in CD81 engagement (81). To further quantify the glycoprotein 
binding capacity of CHO-SR-BI cells, we performed a titration of sE2 from 1-
50$g/ml, bound glycoprotein was detected with a known excess of mAb 9/75. 
Envelope protein binding to CHO-SR-BI cells reached saturation at 30$g/ml 
sE2 (Figure 3-4B).  
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Figure 3-2 Activity of rat anti-E2 monoclonal antibodies.  
To test the reactivity of a panel of anti-E2 mAb IgG, strain HCV-1 soluble E2 
(0.5ug/ml) was captured onto GNA lectin coated ELISA plates. Each mAb was 
assessed for its ability to bind immobilised sE2, bound IgG was detected 
using an anti-rat HRP conjugated secondary. The signal recorded for mAb 
binding in the absence of E2 has been subtracted for each plot. The name of 
each mAb and its epitope is shown. Although each mAb recognised HCV-1 
E2 there was a range of relative binding affinities. An irrelevant rat IgG control 
gave a signal of 0.05 (+/-0.01) at 20$g/ml (data not shown). Error bars 
indicate standard deviation (n=3). 
 
97 
 
 
 
Figure 3-3 Ability of anti-E2 mAb to recognise SR-BI bound E2.  
To determine which mAb is most suitable for detecting sE2 bound to SR-BI, 
parental CHO cells or those expressing SR-BI were incubated with strain 
HCV-1 sE2 at 5$g/ml. Bound sE2 was detected using the panel of anti-E2 
mAbs at 1$g/ml and an anti-rat fluorescently conjugated secondary. The cells 
were analysed by flow cytometry. The panels show the detection of sE2 
bound to CHO SR-BI cells by each mAb (unfilled histogram) and an irrelevant 
rat mAb (filled histogram). The name of each mAb is shown along with 
geometric mean fluorescent intensity (GMFI) in brackets. Optimal detection of 
sE2 bound to SR-BI was achieved with mAb 9/75. sE2 did not bind to parental 
CHO cells, giving GMFI=3.6 when detected using 9/75 (data not shown). 
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 Figure 3-4 Soluble HCV E2 binding to cell expressed SR-BI.  
A. CHO (filled histogram) or CHO-SR-BI (unfilled histogram) cells were 
incubated with 5ug/ml strain HCV-1 sE2 for 1 hr. Bound sE2 was 
detected by flow cytometry using rat anti-E2 mAb 9/75 (5$g/ml) and a 
fluorescently conjugated secondary. B. Titration of sE2 binding; 
saturation of E2 binding to CHO-SR-BI cells (closed circles) was 
achieved at 30$g/ml sE2. No sE2 binding to CHO cells (open circles) 
could be detected. 
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3.3 The interaction of sE2 with a panel of SR-BI mutants. 
Lipoproteins are heavily implicated in HCV-SR-BI interactions; native HCV 
has been proposed to interact with SR-BI via associated apoproteins (190) 
and HDL enhances HCV infection in a process requiring selective cholesterol 
uptake by SR-BI (25, 79, 324). We were therefore interested to investigate 
whether mutations that perturb SR-BI interactions with lipoproteins affect 
envelope protein binding. We used a panel of 6 SR-BI mutants expressed in 
CHO cells, provided by our collaborator Thierry Huby at INSERM in Paris. Of 
the 6 mutants, 2 are unable to mediate cholesterol transfer (121), 1 bears a 
common human polymorphism linked to alterations in plasma lipid levels (1) 
and 3 carry mutations in alpha-helical domains believed to be important for 
SR-BI conformation (Figure 3-5 and Table 3-1).  
 
We hypothesised that one or more of the mutations would modulate the 
binding of HCV sE2 and that this may correlate with the mutant’s ability to 
exchange cholesterol with HDL. To test this we performed SR-BI staining and 
sE2 binding assays in parallel. A saturating concentration of sE2 was used to 
ensure detection of any changes in glycoprotein binding to the mutants. We 
observed variation in the cell surface expression of the mutants, in each case 
sE2 binding was proportional to surface SR-BI levels, this suggests that the 
mutations do not modulate sE2 interaction (Figure 3-6). 
 
Anti-SR-BI mAbs 3D5 and C11 have been previously shown to inhibit HCVcc 
infection, sE2 binding to CHO-SR-BI cells and SR-BI mediated cholesterol 
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transport from HDL (60). The epitopes recognised by these antibodies have 
yet to be identified, we therefore studied their binding to the panel of SR-BI 
mutants. We would expect that if a mutation falls within a mAb epitope it 
would perturb its binding.  Table 3-2 displays the geometric mean fluorescent 
intensity (GMFI) of polyclonal SR-BI, sE2, mAb 3D5 and C11 bound to each 
of the mutants. Figure 3-7 displays the data expressed as a function of cell 
surface SR-BI expression. For each reagent tested, GMFI was proportional to 
mutant SR-BI cell surface expression, indicating that the mutations had not 
altered interaction with mAb or E2. 
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Figure 3-5 Position of SR-BI mutations.  
A schematic representation of SR-BI displaying the mutations listed in 
Table 3-1. 
 
 
Table 3-1 SR-BI mutations.  
The amino acid change and position of each mutation. M1 targets a 
known human SR-BI polymorphism, M2 and M5 target residues 
reported to prevent HDL binding, M3,M4 and M6 are in predicted 
alpha-helical domains. M2 and M5 are unable to mediate cholesterol 
transfer. 
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Figure 3-6 Expression of SR-BI mutants in CHO cells.  
CHO cells stably transfected to express a panel of SR-BI mutants were 
analysed for expression (black histogram) and ability to bind HCV-1 
sE2 (30$g/ml) (red histogram). Panels indicates the name of each 
mutant. 
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 Table 3-2 Investigation of cell expressed SR-BI mutants.  
The table displays the binding of rabbit pre-immune serum (1/500), 
anti-SR-BI serum (1/500), sE2 (30$g/ml), mAb 3D5 (5$g/ml) and mAb 
C11(5$g/ml) to CHO cells expressing wt or mutant SR-BI. Binding was 
assessed by flow cytometry and the data shown are GMFIs. 
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Figure 3-7 Antigenic characterisation of SR-BI mutants.  
Using the GMFI data shown in  Table 3-2, the binding of A. sE2, B. 
mAb 3D5 and C. mAb C11 to the SR-BI mutants was expressed as a 
function of surface SR-BI expression: assessed with polyclonal SR-BI 
sera. Each plot shows parental CHO cells (unfilled circle), those 
expressing wt SR-BI (red circle) and the SR-BI mutants (filled circles). 
For each mutant the binding of sE2, 3D5 and C11 was proportional to 
surface SR-BI expression, suggesting that the mutations do not 
modulate E2 or antibody recognition. This data set is representative of 
multiple experiments. 
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3.4 Expression of SR-BII in CHO cells. 
SR-BII is a variant of SR-BI that differs in its C-terminal intracellular region. It 
is believed to bind all SR-BI ligands, however in rodent livers it has been 
reported to be expressed predominantly intracellularly, it traffics via clathrin 
coated vesicles (88, 89, 223, 330). We aimed to investigate whether SR-BII 
can function as a receptor for HCV entry by generating TRIP lentiviral vectors 
(347) encoding SR-BII (documented in section 2), allowing exogenous 
expression in CHO cells. Figure 3-8 displays the binding of polyclonal anti-SR-
BI serum and sE2 to parental CHO, CHO-SR-BI and CHO TRIP SR-BII. The 
anti-SR-BI serum is directed against the extracellular region of the molecule 
and is cross reactive for SR-BII; cell surface expression of SR-BI and II were 
comparable. A polyclonal anti-serum specific for the C-terminal region of SR-
BII was not reactive with CHO or CHO-SR-BI cells, indicating specific 
transduction with the TRIP lentivirus vector. Both receptors bound sE2, 
suggesting that SR-BI and II share HCV envelope protein as a ligand.  
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Figure 3-8 Expression of SR-BII in CHO cells.  
CHO cells were transduced with a TRIP lentivirus vector expressing 
human SR-BII. CHO, CHO-SR-BI and CHO TRIP SR-BII cells were 
evaluated for their ability to bind rabbit anti-SR-BI serum (1/500), rabbit 
anti-SR-BII serum (1/100) and HCV-1 sE2 (30$g/ml). Anti-SR-BI bound 
to CHO SR-BI/II cells, anti-SR-BII sera bound specifically to CHO TRIP 
SR-BII cells. SR-BII confers sE2 binding to CHO cells. 
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3.5 Discussion. 
We have demonstrated that expression of SR-BI in a CHO cell background 
permits the examination of HCV glycoprotein-SR-BI interactions in isolation 
from other receptors such as human CD81. This is consistent with reported 
findings (274). Using a panel of anti-E2 mAbs specific for non-overlapping, 
consecutive epitopes we were able to determine epitope availability on 
glycoprotein bound to SR-BI. mAb 9/75 recognised sE2 bound to SR-BI with 
the highest signal, however mAbs 3/11, 11/20 and 6/1a also detected 
glycoprotein (Figure 3-3). Interestingly, the epitopes recognised by three of 
these antibodies (9/75, 3/11 and 11/20) are critical for E2-CD81 interactions 
(81, 99, 237), suggesting that interaction of E2 with SR-BI may not preclude 
CD81 engagement. 
 
SR-BI mediated lipoprotein metabolism has been implicated in HCV 
attachment and entry (25, 210, 324, 326). We therefore investigated the 
binding of sE2 to a panel of SR-BI mutants, some of which are unable to 
mediate cholesterol exchange with HDL. sE2 binding to these mutants was 
proportional to their cell surface expression, indicating that SR-BI-E2 
interactions were unaltered (Figure 3-6 and 3-7) mAbs 3D5 and C11 have 
previously been shown to inhibit HCVcc infection and SR-BI mediated 
cholesterol exchange with HDL (60). We attempted to map amino acid 
residues that are important for mAb binding by monitoring their binding to the 
panel of SR-BI mutants. Again, binding was proportional to surface 
expression, suggesting that the mutations did not modulate antibody binding 
(Figure 3-7 & Table 3-2). 
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It would be more appropriate to measure mutant SR-BI receptor activity using 
an in vitro model of viral entry such as the HCVpp system. We therefore 
attempted to render CHO-SR-BI cells permissive to HCVpp infection by 
exogenous expression of CD81 and CLDN1. These cells were readily infected 
by control pseudo-particles expressing VSV glycoproteins, indicating that 
CHO cells support the expression of the GFP reporter gene, however HCVpp 
failed to infect the cells (data not shown). This suggests that either the HCV 
receptors are inappropriately expressed in a CHO cell background or further 
co-receptor(s) await identification. 
 
In the time since this work was completed reports have indicated that residues 
119, 153, 163 and 168 of the SR-BI extracellular loop may be important for E2 
interaction (J.Bwanali et. al. 14th International Symposium on HCV and 
personal communication); the mutants used in this study do not cover these 
sites. These putative E2 binding residues are not currently believed to be 
involved in the interaction of SR-BI with any of its natural ligands, however it 
would be interesting to study whether SR-BI remains biologically functional 
when engaged by HCV. 
 
A recent publication on Plasmodium infection of hepatocytes suggests that 
SR-BI mediated delivery of cholesterol directly to the plasma membrane alters 
CD81 localisation, resulting in increased Sporozoite invasion (339). The two 
SR-BI mutants unable to mediate selective cholesterol transfer (Table 3-1), 
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may offer a tool to study the importance of cholesterol delivery for HCV 
infection and are worthy of re-investigation. 
 
We successfully generated TRIP viral vectors capable of transducing CHO 
cells to express human SR-BII. Exogenous protein expression was monitored 
with SR-BI/II specific antibodies and CHO-SR-BII cells bound sE2 (Figure 
3-8), indicating that SR-BII may act as a HCV entry receptor. Validation of the 
TRIP vectors, allowed us to use them in studies to investigate the role of SR-
BI/II in HCV entry. 
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4 Results: Scavenger Receptor BI and BII Expression Levels Modulate 
HCV Infectivity. 
We aimed to use the tools developed during the previous chapter to 
investigate the importance of SR-BI/II in HCV infection. To address this it was 
necessary to carry out work using the recently developed HCVcc system.  
 
4.1 Over expression of SR-BI/II in Huh-7.5 cells. 
Huh-7.5 cells are a human hepatoma cell line isolated by Keril Blight and co-
workers that are highly permissive to HCV replication (37). They contain a 
mutation in the retinoic acid-inducible gene I, which encodes a protein 
responsible for detection of intracellular viral RNA, an important component in 
the Interferon induction pathway (299, 345). As a result HCVcc can establish 
a robust and prolonged infection of these cells.  
 
Koutsoudakis et. al. established that HCV infection of Huh-7.5 cells is 
dependent on a critical level of CD81 expression and that susceptibility to 
HCV increased at higher CD81 density (159). We aimed to investigate 
whether this was the case for SR-BI. However, at the present time there are 
no human hepatoma cell lines that do not express SR-BI. Moreover, our 
attempts to silence SR-BI using siRNA targeting have been unsuccessful 
(data not shown) and previous studies suggest that it is an inappropriate tool 
for investigating HCV entry (171, 326). Therefore to study HCVcc dependence 
on SR-BI/II expression levels we employed the TRIP lentivirus system, 
validated earlier (page 105), to over express SR-BI and II in Huh-7.5 cells.   
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Figure 4-1A displays endogenous and exogenous expression of SR-BI in 
Huh-7.5 cells. Surface SR-BI/II expression was determined on live cells using 
anti-serum directed against their common extracellular loop; transduction with 
TRIP SR-BI increased plasma membrane expression by ~3 fold, lentivirus 
encoding SR-BII led to only ~2 fold increase (MFIs; Huh-7.5 =115, TRIP SR-
BI = 350, TRIP SR-BII = 213). Staining of fixed and permeablised cells with 
antibodies directed against the differential C-terminal domains of SR-BI and II 
demonstrated that transduction by either respective TRIP vector was specific. 
These anti-sera indicate that total SR-BI and II expression were increased two 
fold in either cell line, suggesting comparable levels of transduction, therefore 
the lower SR-BII surface levels probably reflect a more intracellular 
expression pattern, as would be expected in a hepatoma cell line. This is 
supported by images shown in Figure 4-1B; Huh-7.5 TRIP SR-BI cells display 
cell junctional staining indicating surface expression, whereas the TRIP SR-
BII cells show a diffuse staining throughout the cytoplasm. 
 
As a control Huh-7.5 cells were transduced to over express CD9, a 
tetraspanin thought to play no role in HCV infection, these cells display a ~13 
fold increase in CD9 expression (data not shown). CD81 levels, cell viability 
and proliferation remained unaltered in each of the Huh-7.5 TRIP cell lines 
(data not shown).  
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Figure 4-1 Over expression of human SR-BI/II in Huh-7.5 cells. 
A. SR-BI/II expression was determined by flow cytometry using 
extracellular (EC) domain specific anti-SR-BI serum (on live cells) and 
C-terminus specific antisera capable of discriminating between SR-BI 
and SR-BII (on fixed and permeabilized cells). Each panel displays the 
isotype control (filled), parental (solid line), and transduced (dashed line) 
Huh-7.5 cells. B. Huh-7.5 TRIP cell lines were methanol fixed and 
stained with an SR-BI/II EC domain specific mAb suitable for 
immunofluorescence (mAb anti-Cla-1), images were taken at X200 
magnification. 
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4.2 Exogenous expression of SR-BI/II in Huh-7.5 cells enhances HCVcc 
infection. 
To investigate the effect of increased SR-BI/II surface expression on HCV 
infection, the Huh-7.5 TRIP cells were inoculated with J6/JFH virus (179) for 
1-8 hrs followed by 72 hrs infection (Figure 4-2A). Infection of Huh-7.5 TRIP 
SR-BI and BII was enhanced by ~3 fold and ~2 fold respectively at all 
inoculation time points, suggesting that SR-BI/II surface expression limits 
HCVcc infection. To study intra-genotype dependence on SR-BI/II, parallel 
infections with J6/JFH and JFH-1 were carried out (Figure 4-2B). In contrast to 
J6/JFH, JFH-1 infection increased ~18 and ~6 fold in Huh-7.5 cells over 
expressing SR-BI and II, respectively. This implies that JFH-1 has a higher 
dependence on SR-BI/II than J6/JFH chimeric virus. Over-expression of CD9 
did not enhance the infection of either genotype. 
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Figure 4-2 Over expression of SR-BI and SR-BII in Huh-7.5 cells 
enhances HCVcc infection.  
A. Parental (open circles) and transduced Huh-7.5 cells over expressing 
human CD9 (filled circles), SR-BI (open squares), or SR-BII (filled 
squares) were incubated with J6/JFH for various times between 1 and 8 
hrs; unbound virus was removed by washing, and the infection allowed 
to proceed for 72 hrs.  Both SR-BI and SR-BII transduced cells show 
elevated levels of infection. Virus infectivity is expressed as the number 
of NS5A-positive cells, or infected units (IU)/ml. B. Parental and 
transduced cells were incubated with J6/JFH (white bars) or JFH-1 (grey 
bars) for 1 hr, followed by a 72 hr infection. Infected cells were visualized 
by staining for intracellular NS5A, and infectivity for transduced cells 
expressed relative to the parental cells. J6/JFH and JFH-1 infectivities 
for parental Huh-7.5 cells were 11,000 +/- 3,000 IU/ml and 2,400 +/- 900 
IU/ml, respectively. ** p=0.001 * p=0.024 (unpaired t-test). The error 
bars indicate standard deviation from the mean (n=5). 
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4.3 Evidence of enhanced JFH-1 transmission in cells over expressing 
SR-BI. 
By allowing an infection to proceed for 72 hrs it is possible to observe both 
primary entry events and secondary rounds of infection following virus 
replication and de novo virion production. A characteristic of secondary 
infection is the appearance of HCV antigen positive cell foci, in JFH-1 infected 
Huh-7.5 cells the foci typically contain between 4 and 20 infected cells. We 
observed an increase in the size of infected foci upon over expression of SR-
BI, although apparent in J6/JFH infected cells, this phenotype was particularly 
pronounced in JFH-1 infection (Figure 4-3A).  
 
We quantified the differences in focus size by enumerating the number of 
infected cells per focus in JFH-1 infected Huh-7.5 and TRIP SR-BI cells. The 
foci were categorised as either small (1-2 cells/focus), medium (3-10), large 
(11-30) or very large (31-100). Figure 4-3B displays the percentage of foci that 
fall into each category, over expression of SR-BI increased the frequency of 
large and very large foci. However, presenting the data in this manner under-
represents the contribution of large and very large foci to overall infected cell 
number. Therefore, Figure 4-3C presents the same data as the percentage of 
total infection occurring within each focus category. In this representation the 
effect of SR-BI over expression is more distinct; ~70% of infected Huh-7.5 
TRIP SR-BI cells reside in large or very large foci, compared to only 20% of 
infected parental cells. These data suggest that increased focal size is a major 
contributor to enhanced infection of Huh-7.5 TRIP SR-BI cells by JFH-1. 
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Figure 4-3 Over expression of SR-BI and SR-BII in Huh-7.5 cells 
increases infected cell focus size.  
A. Parental and Huh-7.5 cells over expressing human CD9, SR-BI, or 
SR-BII were incubated with JFH-1 for 1 hr, and the infection allowed to 
proceed for 72 hrs. Infected cells were visualized by staining for NS5A 
(green), and the nuclei counterstained with DAPI. The images were 
taken at X100 magnification, scale bars represent 60$m. Quantification 
of focus size in parental (white bars) and Huh-7.5 TRIP SR-BI cells 
(grey bars): the number of infected cells within each focus was counted 
allowing foci frequency distribution across 4 size categories (1-2, 3-
10,11-30 and 30-100 cells/focus). The data is expressed in B. as the % 
of foci within each category and in C. as the % of total infected cells 
that reside within each category. In Huh-7.5 TRIP SR-BI cells ~70% of 
infected cells resided in large or very large foci compared to only ~20% 
for parental Huh-7.5 cells. Error bars indicate standard deviation from 
the mean (n=3). 
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4.4 SR-BI expression levels limit the entry of HCV pseudo-particles. 
HCVpp comprise a replication deficient retrovirus core and as such are only 
capable of a single round of infection (24, 130), allowing the investigation of 
primary HCV entry in isolation from downstream replication events. Huh-7.5 
TRIP cell lines were infected with JFH-1 or control murine leukaemia virus 
(MLV) pseudo-particles and infection analysed by flow cytometric detection of 
a GFP reporter gene (Figure 4-4). MLVpp infection was unaltered in the Huh-
7.5 TRIP cells, HCVpp – JFH-1 was enhanced two fold by over expression of 
SR-BI and II, indicating that SR-BI/II surface expression is limiting for HCV 
entry. However, this increase in infection is much smaller than that seen in 
JFH-1 HCVcc (Figure 4-2B), this is probably due to the lack of secondary 
infection in the HCVpp system and the fact that pseudo-particles may be a 
relatively poor mimic of authentic HCV virions.  
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Figure 4-4 Over expression of SR-BI and SR-BII in Huh-7.5 cells 
enhances HCVpp-JFH infection.  
Parental and Huh-7.5 cells over expressing human CD9, SR-BI, or SR-
BII were incubated with murine leukaemia virus pseudo-particles 
(MLVpp) (white bars) or HCVpp - JFH-1 (grey bars), for 8 hrs, followed 
by a 72 hr infection. Infection was realised by flow cytometric detection 
of a pseudo-particle encoded GFP reporter gene. Over-expression of 
SR-BI/II enhanced HCVpp - JFH-1 infection by ~2 fold, MLVpp infection 
remained unaltered. * = <0.04 (unpaired t-test) Errors bars indicate 
standard deviation from the mean (n=3). 
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4.5 Murine SR-BI does not enhance HCVcc infection. 
Murine SR-BI is believed to be indistinguishable from human in regards to 
ligand binding and metabolism, indeed a number of studies have used murine 
SR-BI expressed in human hepatoma cell lines to study cholesterol uptake 
and trafficking (279, 300). HCV sE2 does not bind to murine SR-BI (274), 
however if HCV interaction with SR-BI occurs via apoproteins associated with 
the particle (190) both human and murine forms of SR-BI may act as co-
receptors. To investigate this we challenged Huh-7.5 cells expressing murine 
SR-BI with JFH-1. The anti-SR-BI serum used in previous experiments is 
reactive against both species, therefore an N-terminal GFP tagged form of 
murine SR-BI (GFP-moSR-BI) was used, allowing flow cytometric detection of 
positive cells. Importantly, the GFP-SR-BI construct has previously been 
shown to be functional in regards to lipid uptake and metabolism (279). Figure 
4-4A displays un-transfected Huh-7.5 cells and those expressing GFP-moSR-
BI, ~18 % are positive for exogenous murine SR-BI. Gating of GFP-moSR-BI 
positive and negative Huh-7.5 cells allowed quantification of JFH-1 infection 
within each population (Figure 4-4B). Expression of murine SR-BI did not 
enhance JFH-1 infection of Huh-7.5 cells (Figure 4-4B & C), suggesting that 
HCV dependence on SR-BI is driven by a specific HCV E2-receptor 
interaction and not by apoprotein association. 
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4.6 SR-BI/II expression levels modulate plasma-derived J6/JFH 
infectivity.  
The production of HCV virions is believed to be dependent on the assembly 
and secretion of VLDL, indeed Huh-7.5 are thought to produce HCV lipo-viro-
particles (63, 109, 131, 224). However, it is accepted that the HCVcc system 
is only a surrogate model of in vivo virion production and as such may not 
support authentic HCV-lipoprotein associations. Numerous studies have 
shown that HCVcc is infectious in animal models such as the chimpanzee 
(144, 180), virus recovered from infected subjects have a lower buoyant 
density than cell culture virus (180), suggesting increased lipoprotein 
association. We therefore used J6/JFH virus recovered from the plasma of 
infected uPA-SCID mice with transplanted human livers (208, 209), to 
investigate the relationship between plasma derived virus and SR-BI/II.  
 
J6/JFHplasma infection of Huh-7.5 cells was enhanced by over expression of 
SR-BI/II in a comparable manner to J6/JFHHCVcc(Figure 4-5 A)suggesting that 
J6/JFHplasma virus has a similar dependence for SR-BI to virus produced in 
vitro. However, Maillard et. al. reported that human sera derived HCV may 
interact with SR-BI via associated apoproteins and not virion envelope 
proteins (190). To address the importance of E2 glycoproteins in J6/JFHplasma 
infection we pre-incubated particles with ant-E2 mAb C1 prior to inoculation of 
Huh-7.5 cells (Figure 4-5 B). Both plasma and cell culture derived J6/JFH are 
neutralised by mAb C1, this implies that E2 is essential for infection by either 
virus. mAb C1 is reported to inhibit E2-CD81 interaction (172), however its 
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effect on SR-BI-E2 binding is not known and therefore it is difficult to 
speculate on the exact mode of neutralisation. 
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Figure 4-5 Over expression of SR-BI and SR-BII in Huh-7.5 cells 
enhances the infectivity of cell culture- and plasma derived J6/JFH.  
A. Parental and Huh-7.5 cells over expressing human CD9, SR-BI, or 
SR-BII were incubated with J6/JFH derived from cell culture 
(J6/JFHHCVcc; white bars) or from the plasma of infected chimeric mice 
(J6/JFHplasma; grey bars) for 6 h, followed by a 72 hrs infection. Infected 
cells were visualized by staining for intracellular NS5A, and infectivity for 
transduced cells expressed relative to the parental cells. J6/JFHcc and 
J6/JFHplasma infectivities for parental Huh-7.5 cells were 35,000 (+/- 
1,300) IU/ml and 2,250 (+/-700) IU/ml, respectively. B. Comparable 
levels of infectious virus from the two sources were incubated with anti-
E2 mAb C1 and a control anti-dengue virus mAb at 10$g/ml for 1 hr prior 
to infecting Huh-7.5 cells. Infectivity was measured by quantifying NS5A-
positive cells, and the percent neutralisation of C1 defined by comparing 
infectivity in the presence of an anti-dengue virus mAb. Error bars 
indicate the standard deviation from the mean (n=2). 
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4.7 Anti-SR-BI serum inhibits cell culture and plasma derived J6/JFH 
infection. 
We have used cells over expressing SR-BI to demonstrate that SR-BI levels 
modulate HCVcc and HCVplasma infection. In the absence of robust siRNA 
silencing of SR-BI we employed anti-SR-BI sera to limit receptor availability 
during J6/JFHHCVcc/plasma infection (Figure 4-6A). Pre-incubation of Huh-7.5 
cells with anti-SR-BI inhibits cell culture and plasma derived J6/JFH infection 
equally (Figure 4-6B), an anti-CD81 antibody was used as a positive control. 
To investigate whether the anti-serum is capable of preventing HCV E2-SR-BI 
interactions, we treated CHO SR-BI cells prior to performing a sE2 binding 
assay (Figure 4-6C). A known sub saturating concentration of anti-serum 
reduced sE2 binding to CHO-SR-BI cells by ~3 fold. Taken together these 
data support a model where HCV infection of Huh-7.5 cells is limited by the 
expression of SR-BI/II. 
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Figure 4-6 Anti-SR-BI serum inhibits cell culture- and plasma-
derived J6/JFH infectivity.  
A. Anti-SR-BI reactivity for Huh-7.5 cells (open circles), control pre-
immune rabbit serum was tested at the highest dilution (filled circles). 
The data are expressed as the mean fluorescence intensity (MFI). B. 
Huh-7.5 cells were incubated with anti-SR-BI and control pre-immune 
sera at 1:500 or anti-CD81 MAb M38 and control isotype matched IgG at 
1$g/ml for 1 hr prior to infection with cell culture (white bars) or plasma 
derived (grey bars) J6/JFH. Infectivity was measured by quantifying 
NS5A-positive cells, and the percent neutralisation of the receptor-
specific antibodies determined by comparing infectivity in the presence 
of the control antibodies. Anti SR-BI and anti-CD81 inhibit the infectivity 
of both viruses. C. Parental CHO cells or those expressing SR-BI were 
pre-incubated with control rabbit serum (white bars) or anti-SR-BI (grey 
bars) at 1/400 prior to incubation with HCV-1 sE2 at 5$g/ml, cell-bound 
E2 was detected with 1$g/ml mAb 9/75. Data are expressed as mean 
fluorescence intensity (MFI). Anti-SR-BI inhibits HCV sE2 interaction 
with SR-BI expressed on CHO cells. Error bars indicate standard 
deviation from the mean (n=3). 
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4.8 Cell culture adaptation of JFH-1 HCVcc reduces SR-BI dependency. 
Numerous studies have documented cell culture adaptation of HCVcc during 
prolonged infection of human hepatoma cell lines (37, 144, 269, 352). We 
investigated the effect of adaptation on SR-BI dependence using a JFH-1 
strain that had undergone multiple passages in Huh-7.5 cells. Although the 
occurrence of mutations has not been confirmed by sequencing, JFH-1adapted 
virus is more infectious than wild type (wt) virus (data not shown) suggesting 
an accumulation of selective mutations. In this study JFH-1 wt infection of 
Huh-7.5 TRIP SR-BI cells was enhanced ~10 fold, in contrast JFH-1adapted 
infection increased only ~3 fold (Figure 4-7). This data suggests that 
adaptation of JFH-1 HCVcc to Huh-7.5 cells involves an alteration in SR-BI 
dependence. This is consistent with SR-BI availability being a rate limiting 
factor during wt HCV infection of Huh-7.5 cells. 
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Figure 4-7 Infection of Huh-7.5 over expression SR-BI by cell 
culture adapted JFH-1 HCVcc.  
Parental and Huh-7.5 over-expressing SR-BI were inoculated for 1 hr 
with wt JFH-1 or virus that had been selected for high extracellular virus 
infectivity. The infection was allowed to continue for 72h, the data is 
expressed relative to infection of parental Huh-7.5 cells. wt virus 
infection is enhanced by ~10 fold whereas adapted JFH-1 infection 
increases only ~3 fold. Errors bars represent standard deviation (n=3).  
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4.9 Discussion. 
Over expression of SR-BI in Huh-7.5 cells increases their susceptibility to 
HCVcc (Figure 4-2), indicating that infection is limited by SR-BI expression 
levels. We made similar, though less pronounced, observations using cells 
over expressing the splice variant SR-BII, suggesting that it is a functionally 
active receptor for HCV attachment and/or entry (Figure 4-2). Comparable 
findings were reported for CD4 and chemokine receptor expression levels 
influencing human immunodeficiency virus cell entry (13, 249).  
 
Over expression of SR-BI enhanced JFH-1 infectivity to a much greater extent 
than J6/JFH; 18-fold and 3-fold, respectively (Figure 4-2), suggesting strain 
specific variation within genotypic clades. HCVpp expressing diverse 
glycoproteins vary in their ability to infect HepG2 cells expressing CD81, 
supporting a model of genotypic variants with different dependencies for the 
viral co-receptors (101, 202). 
 
HCVpp-JFH-1 infection of Huh-7.5 cells over expressing SR-BI was enhanced 
2 fold indicating that the restriction occurs at the point of virus entry (Figure 
4-4). However, this increase in HCVpp infection, was much less pronounced 
than that seen with JFH-1 HCVcc, suggesting a disparity between the two 
model systems. This discrepancy may be accounted for by the increase in 
JFH-1 infected cell focus size in cells over expressing SR-BI, as foci occur 
following multiple rounds of replication and HCVpp do not mimic this process. 
The fact that a large proportion of JFH-1 infected Huh-7.5 TRIP SR-BI cells 
reside in large foci (Figure 4-3) suggests that the phenotype seen in these 
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cells is largely manifested in secondary and local transmission. It has been 
recently shown that HCV is able to transfer infectivity between cells, resulting 
in the formation of large infected cell foci (314). Our data suggest that SR-BI 
promotes this route of transmission. 
 
J6/JFH is infectious in vivo and virus recovered from infected animal models 
can be recultured in vitro. These HCVplasma particles are of a lower buoyant 
density and are thought to represent the particle-lipoprotein associations 
found in human plasma (180). SR-BI over expression enhanced plasma 
derived virus in a comparable manner to cell culture virus and anti-SR-BI 
serum inhibited the infection of both viruses (Figure 4-5 & Figure 4-6). The 
infectivity of both viruses was neutralised by anti-E2 mAb C1 (Figure 4-5), 
indicating that HCVplasma particle entry is dependent on viral envelope proteins 
in an analogous manner to HCVcc. These data suggest that particle 
associated lipoproteins do not alter the relationship with SR-BI, a view 
supported by our findings using murine SR-BI (Figure 4-4). This implies that 
HCVcc particles do not interact non-specifically with murine-SR-BI via 
associated apoproteins and that a specific interaction between HCV E2 and 
human SR-BI is necessary for enhanced infection in over expressing cells. 
 
Interestingly, infection of Huh-7.5 cells over expressing SR-BI by a cell culture 
adapted JFH-1 variant was only enhanced ~3 fold (Figure 4-7). This 
observation suggests that adaptation to Huh-7.5 leads to a lower dependency 
on SR-BI and consequently its expression levels do not limit infection to the 
same extent. The adaptation of viruses to cell culture is a well documented 
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phenomenon, but the characteristics of these viruses differ from wt making it 
difficult to reconcile findings in vitro with the situation within a natural host (14, 
136, 263, 270). However, when used appropriately adapted mutants are tools 
to examine the complex interactions between a virus particle and its 
receptor(s) (315, 335). 
 
The work covered in this chapter has been published in the Journal of 
Virology -  Grove, J., T. Huby, Z. Stamataki, T. Vanwolleghem, P. Meuleman, 
M. Farquhar, A. Schwarz, M. Moreau, J. S. Owen, G. Leroux-Roels, P. Balfe, 
and J. A. McKeating. 2007. Scavenger receptor BI and BII expression levels 
modulate hepatitis C virus infectivity. J Virol 81:3162-9. 
131 
5 Results: Identification of a residue in hepatitis C virus E2 
glycoprotein that determines scavenger receptor BI and CD81 
receptor dependency and  particle sensitivity to neutralising 
antibodies. 
 
In the previous chapter we established that SR-BI expression levels limit 
HCVcc infection of Huh-7.5 cells (Figure 4-2), furthermore a cell culture 
adapted strain of JFH-1 exhibited an altered dependence on SR-BI (Figure 
4-7). To investigate this further we obtained a characterised JFH-1 cell culture 
adapted virus from Jin Zhong and Frank Chisari of the Scripps Institute in La 
Jolla. This mutant virus carries a single amino acid change of glycine to 
arginine within the E2 glycoprotein; at position 451 of the polyprotein. Zhong 
et. al. have previously reported that JFH-1 G451R has a higher specific 
infectivity than JFH-1 wt and an altered relationship between particle density 
and infectivity, suggesting changes in particle-lipoprotein interactions. 
 
5.1 JFH-1 G451R has a reduced dependence on SR-BI.  
To investigate whether the G451R mutation alters SR-BI dependence in a 
manner similar to that seen in Figure 4-7, parental Huh-7.5 and cells 
transduced to over express SR-BI were infected with JFH-1 wt and G451R. 
We previously reported that HCV can infect hepatoma cells via cell-free and 
cell-cell routes (314). To discriminate between cell-free particle primary 
infection and secondary transmission events, infection was allowed to 
proceed for 48 and 72 hrs, respectively (314). Over expression of SR-BI 
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enhanced the infectivity of JFH-1 4-fold at 48 hrs post infection and this 
increased to 8-fold by 72 hrs (Figure 5-1A). At 72 hrs the increased infectivity 
was associated with an increase in the size of infected cell foci comparable to 
that seen in Figure 4-3 (data not shown), suggesting increased cell-cell 
transfer of infection. In contrast, JFH-1 G451R showed 1.5-fold increase in 
infectivity at both time points with no change in focal size (Figure 5-1A). 
 
To further investigate JFH-1 G451R interaction(s) with SR-BI we employed 
the neutralising rabbit anti-SR-BI serum characterised in Figure 4-6 (120, 
190). Huh-7.5 cells were pre-incubated with the anti-SR-BI sera prior to 
challenging with JFH-1 wt or G451R. Whilst the infectivity of both viruses was 
inhibited, JFH-1 G451R is less sensitive to neutralisation; a 1/100 dilution of 
antiserum reduced JFH-1 G451R infectivity by 20%, compared to 80% for wt 
virus (Figure 5-1B).  
 
It is widely reported that HDL enhances HCV infection via an SR-BI 
dependent mechanism requiring the transfer of lipids from HDL (25, 80, 324). 
To ascertain whether the altered relationship of G451R with SR-BI extends to 
lipoprotein enhancement, JFH-1 wt and G451R infections were supplemented 
with 10µg/ml HDL. HDL promoted JFH-1 wt infectivity 2-fold, consistent with 
previous reports, however G451R infectivity was unaltered (Figure 5-1C). 
Taken together, these data suggest that cell culture adaptation reduces the 
requirement for SR-BI during virus entry.  
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Figure 5-1 JFH-1 G451R has an altered dependence on SR-BI.  
A. Huh-7.5 cells over expressing SR-BI were incubated with JFH-1 wt (grey 
bars) or JFH-1 G451R (white bars) for 8 hrs. Cells were fixed after 48 and 72 
hrs, stained for NS5A and the mean number of infected cells per well 
determined. Infectivity is expressed relative to parental Huh-7.5 cells. At 72 
hrs JFH-1 wt infection is enhanced ~8-fold whereas G451R remains largely 
unaltered (~1.5-fold) B. Huh-7.5 cells were incubated with a serial dilution of 
rabbit anti-SR-BI sera for 1 hr prior to challenge with JFH-1 wt (closed circles) 
or JFH-1 G451R (open circles). The data is expressed as percentage 
neutralisation relative to infection of Huh-7.5 cells treated with control rabbit 
sera. JFH-1 wt is inhibited by anti-SR-BI, G451R is not. C. Huh-7.5 cells were 
inoculated with JFH-1 wt or JFH-1 G451R in the presence of 10µg/ml high 
density lipoprotein (HDL). Infection is expressed relative to infection in the 
absence of HDL. HDL promotes JFH-1 wt infectivity 2-fold but has no 
significant effect on JFH-1 G451R, ** p=0.0069 (unpaired t-test). Error bars 
indicate standard deviation from the mean (n=3). 
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5.2 Cell culture adapted JFH-1 G451R has an increased sensitivity to 
neutralisation by soluble CD81.  
Having established that the G451R mutation alters the relationship between 
HCV and SR-BI, we wanted to investigate the effects of this mutation on 
CD81-dependent routes of entry. Huh-7.5 cells were incubated with anti-CD81 
mAbs prior to infecting with JFH-1 wt or G451R. The infectivity of both viruses 
was reduced, however JFH-1 G451R was less sensitive to treatment by anti-
CD81 mAbs (Figure 5-2A & B). We and others have reported that a soluble 
form of human CD81 LEL (hCD81 LEL) interacts with the viral gps and inhibits 
HCV infectivity (24, 101, 130, 179). JFH-1 G451R demonstrated an increased 
sensitivity to neutralisation by hCD81 LEL, with 10-fold less protein required to 
reduce infectivity by 50% (Figure 5-2C), suggesting an increased exposure or 
affinity of CD81 binding residues on the mutant viral gps. 
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Figure 5-2 CD81 dependence of JFH-1 wt and G451R infection.  
Huh-7.5 cells were incubated with a serial dilution of  2s131 (A.) or 
1s201 (B.) mouse anti-CD81 mAbs for 1 hr prior to challenge with JFH-1 
wt (closed circles) or JFH-1 G451R (open circles). Lab adapted virus is 
less sensitive to anti-CD81 mAb. JFH-1 wt or G451R viruses were 
incubated with human CD81 LEL for 1 hr prior to infecting Huh-7.5 cells 
(C.). JFH-1 G451R is more sensitive to neutralisation by hCD81 LEL. 
The data is expressed as percentage neutralisation relative to viral 
infection in the presence of an irrelevant mouse IgG or non-active 
mouse CD81 LEL, respectively. Error bars indicate standard deviation 
from the mean (n=3).  
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5.3 sE2 glycoprotein bearing the G451R mutation demonstrates 
increased binding to CD81.  
To investigate whether the G451R mutation modulates E2 binding to SR-BI or 
CD81, soluble forms of JFH-1 wt and G451R E2 were expressed in 293T cells 
and used to quantify receptor interactions (as documented in section 2.7). sE2 
was harvested from the media of cells supplemented with 3% delipidated FBS 
to eliminate the possibility of lipoprotein association(s). CHO cells expressing 
either human SR-BI or CD81 (Figure 5-3A) were incubated with comparable 
amounts of JFH-1 wt or G451R sE2, the bound gps were detected via a C-
terminal tag recognised by mAb 10/76b and quantified by flow cytometry 
(Figure 5-3B). JFH-1 wt sE2 bound specifically to CHO cells expressing either 
SR-BI or CD81, as previously reported for genotype 1 sE2 (99, 120, 274). 
JFH-1 wt and G451R sE2 bound to CHO-SR-BI cells with comparable staining 
intensities, however the mutant protein showed enhanced binding to CD81 
with 50% more CHO-CD81 cells binding G451R sE2 compared to JFH-1 wt 
(Figure 5-3B & C). These data are consistent with the increased sensitivity of 
mutant virus to hCD81 LEL neutralisation.  
 
To further study the interaction of wt and G451R sE2 with CD81 we followed 
the binding of sE2 with hCD81 LEL by enzyme immunoassay. Previous 
studies have reported that the interaction of E2 with CD81 is dependent on 
the dimeric status of CD81 (83, 84). CD81 dimers bound approximately 3-fold 
more JFH-1 G451R than wt sE2 (Figure 5-4A), confirming our earlier studies 
with CHO cell expressed CD81. hCD81 LEL monomers failed to interact with 
wt or mutant sE2 (Figure 5-4B). To further characterize the interaction of 
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G451R sE2 with hCD81 LEL we compared mutant and wt sE2 interactions 
with a panel of CD81 variants with substitutions at amino acid residues 
reported to be critical for interacting with E2 (84). All mutations abrogated 
CD81 interaction with both wt and G451R sE2 proteins, suggesting that the 
G451R mutation does not alter the nature of the E2-CD81 interaction (Figure 
5-4B). 
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Figure 5-3 JFH-1 wt and G451R soluble E2 interaction with CHO 
cells expressing SR-BI and CD81.  
A. CHO cells expressing either human SR-BI (>80% positive) or CD81 
(20-30% positive), were methanol fixed and stained with mAb anti-
CLA1 or anti-CD81 2s139. B. Binding of recombinant JFH-1 wt and 
G451R sE2 to parental CHO, CHO-SR-BI and CHO-CD81 cells. Bound 
E2 was detected with mAb 10/76b. C. The mean fluorescent intensity 
(MFI) of JFH-1 wt (grey bars) and G451R (white bars) sE2 bound to 
CHO-SR-BI and CHO-CD81 cells is shown, the signal from sE2-CHO 
cell interaction was subtracted. JFH-1 G451R sE2 displays enhanced 
binding to CHO-CD81 cells. Error bars indicate standard deviation from 
the mean (n=3). 
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Figure 5-4 JFH-1 wt and G451R soluble E2 interaction with 
recombinant CD81.  
A. Dose dependent binding of JFH-1 wt (grey bars) or G451R (white 
bars) sE2 with human CD81 LEL (hCD81 LEL) dimer. Data is 
represented as the mean optical density (OD) at 450nm.G451R sE2 
demonstrates increased binding to immobilised hCD81 LEL. *** 
p=<0.0001 (unpaired t-test) B. JFH-1 wt or G451R sE2 association with 
PBS, monomeric and dimeric hCD81 LEL and mutants of hCD81 LEL 
that abrogate CD81 interaction with E2. All mutants were characterized 
for their effects on CD81 oligomerization and were shown to have 
minimal effect on dimerization. E2 binding to the mutants is expressed 
relative to CD81 LEL wt dimer. JFH-1 wt and G451R sE2 binding was 
ablated by each of the hCD81 LEL mutations. Error bars indicate 
standard deviation from the mean (n=3). 
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5.4 Relationship between JFH-1 and G451R particle density, infectivity 
and co-receptor interactions.  
HCV particles associate with lipoproteins to form LVPs that can be 
fractionated according to their buoyant density. (8, 179, 180, 215, 233, 312). 
Initial experiments examined the distribution of wt and mutant particles across 
iodixanol gradients by quantifying genome copy numbers in each fraction. Wt 
and mutant viruses demonstrated a similar range of particle densities, 
suggesting comparable physical properties (Figure 5-5 A). Low density 
particles are reported to have the highest specific infectivity (179, 180), in 
support of this we observed peak JFH-1 wt infectivity at a density of 1.09g/ml 
(Figure 5-5 B). In contrast, the majority of JFH-1 G451R infectivity resided in 
the higher density fractions at 1.12g/ml ( Figure 5-5B), suggesting an altered 
relationship between particle density and infectivity.  The RNA copy numbers 
and infectivity data were used to calculate the specific infectivity of particles 
within each fraction (Figure 5-5 C); the G451R adaptation appears to have 
increased the infectivity of higher density particles, whilst perturbing the 
infectivity of those of a low density. 
 
To study the relationship between particle density and receptor dependent 
infection, JFH-1 wt and G451R iodixanol gradient fractions were screened for 
infection of parental and Huh-7.5 cells transduced to over express SR-BI and 
for their sensitivity to neutralisation by SR-BI and CD81 specific antibodies 
(Figure 5-6). We failed to observe any association between wt or mutant virus 
density and SR-BI dependence, with all fractions showing comparable levels 
of infectivity under the respective conditions (Figure 5-6A & B). JFH-1 G451R 
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demonstrated a lower dependence on SR-BI, with minimal inhibition observed 
with the anti-SR-BI antibody (Figure 5-6B). Similar results were observed with 
the anti-CD81 mAb, with all fractions demonstrating a similar sensitivity to 
neutralisation (Figure 5-6C). The lack of correlation between JFH-1 wt and 
G451R particle density and sensitivity to anti-receptor antibodies suggests 
that the mutant phenotype of reduced SR-BI dependence and increased 
sensitivity to hCD81 LEL neutralisation may be largely attributable to an 
altered affinity or interaction of the viral gps with CD81 (Figure 5-3 & Figure 
5-4).  
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 Figure 5-5 Analysis of JFH-1 wt and G451R buoyant density. 
Concentrated JFH-1 wt (closed circles) and G451R (open circles) were 
separated on an iodixanol gradient. A. The number of HCV particles 
per fraction was assessed by quantifying HCV RNA genomes by RT-
PCR. The particle number in each fraction is expressed as a 
percentage of the total for either virus. JFH-1 wt and G451R exhibit 
comparable particle distribution throughout the gradient. B. The 
infectivity per fraction was assessed by inoculating Huh-7.5 cells. The 
infectivity within each fraction is expressed as a percentage of the total 
for either virus. The cell culture adaptation alters the relationship 
between particle density and infectivity. C. The number of infectious 
units (IU) per RNA genome copy were calculated to analyse the 
specific infectivity of particles within each fraction. The G451R mutation 
increases the infectivity of higher density particles whilst reducing the 
infectivity of low density particles. 
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Figure 5-6 Relationship between particle density and co-receptor 
dependency.  
The density fractions containing infectious JFH-1 wt (grey bars) or JFH-1 
G451R (white bars) were used to assess the relationship between 
particle density and SR-BI and CD81 interaction(s). The approximate 
densities of each fraction are indicated on the x-axis. A. Huh-7.5 cells 
over expressing SR-BI were inoculated with JFH-1 wt and G451R virus 
and infectivity expressed relative to parental Huh-7.5 cells. Huh-7.5 cells 
were incubated with either B. anti-SR-BI sera at 1/300 or C. anti-CD81 
1s201 at 0.1µg/ml prior to challenge with infectious fractions of JFH-1 wt 
and G451R. There is no correlation between particle density and 
receptor dependence. Error bars indicate standard deviation from the 
mean (n=3). 
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5.5 Adapted JFH-1 demonstrates an increased sensitivity to nAbs.  
Several reports have suggested that antibodies specific for the HCV gps 
neutralise viral infectivity by inhibiting HCV interaction(s) with CD81 (145, 147, 
237)(reviewed in (295)). Given the increased binding of G451R E2 to CD81 
we were interested to investigate the effects of this mutation on particle 
sensitivity to nAbs. We screened the sensitivity of JFH-1 wt and G451R virus 
to neutralisation by IgG purified from the sera of six HCV infected individuals. 
In each case G451R demonstrated an increased sensitivity to inhibition by 
patient IgG (Figure 5-7A-F). JFH-1 wt was inhibited to varying degrees by the 
patient IgG and in 5 of 6 cases the percentage neutralisation reached a 
plateau below 80%, suggesting that a population of particles were resistant to 
neutralisation. To quantify the increased sensitivity of G451R to antibody-
dependent neutralisation, we determined the concentration of pooled HCV+ 
patient IgG required to inhibit 50% of infectivity (inhibitory concentration, IC50). 
The IC50 for the wt and mutant viruses are 40µg/ml and 0.75µg/ml 
respectively, indicating that G451R is 50-fold more sensitive to neutralisation 
(Figure 5-7G). Patient derived IgG is polyclonal in nature and likely to target 
multiple conformation-dependent epitopes. To study virus neutralisation via a 
defined epitope we screened the sensitivity of both viruses to mAb 3/11, 
specific for E2 amino acids 412–423. G451R showed an increased sensitivity 
to 3/11 neutralisation (Figure 5-7H). These data are consistent with an 
increased sensitivity of G451R particles to nAbs targeting diverse epitopes, 
suggesting an increased availability of epitopes on G451R compared to the 
parental virus. However we failed to detect any difference in HCV+ patient IgG 
or 3/11 binding to immobilised JFH-1 wt or G451R sE2 or to infected cells by 
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flow cytometry (data not shown), indicating that differential epitope 
presentation may only occur in the context of a virus particle. 
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Figure 5-7 JFH-1 G451R demonstrates an increased sensitivity to 
neutralisation by gp-specific antibodies.  
JFH-1 wt (closed circles) or G451R (open circles) were incubated with 
IgG purified from the sera of six HCV infected subjects (A-F) or anti-E2 
mAb 3/11 (H), prior to infecting Huh-7.5 cells. Percent neutralisation was 
calculated by quantifying viral infectivity in the presence of anti-HCV 
specific antibodies relative to HCV negative IgG or irrelevant mAb, 
respectively. G. To determine the concentration of IgG required to 
neutralise 50% of JFH-1 and G451R infectivity (IC50), both viruses were 
incubated with a pool of the six patient derived IgG. The IC50 is depicted 
as a horizontal line. JFH-1 G451R is 50-fold more sensitive to 
neutralisation by pooled patient IgG. Error bars indicate standard 
deviation from the mean (n=3).  
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5.6 Low density JFH-1 particles are less sensitive to nAbs. 
To investigate whether the increased sensitivity of G451R to nAbs was 
attributable to alterations in particle density, the iodixanol gradient fractions of 
wt and mutant viruses were normalized for infectivity and incubated with 
10$g/ml pooled HCV+ patient IgG. For JFH-1 wt, the sensitivity to 
neutralisation increased with particle density with the lower density fraction 
being neutralised by 20%, compared to 80% with the highest (Figure 5-8). In 
contrast, all G451R fractions were neutralised by 100%. Control experiments 
established that iodixanol concentration had minimal effects on JFH-1 
infectivity and sensitivity to IgG neutralisation (data not shown). These data 
provide the first evidence that lipoprotein association of JFH-1 reduces the 
sensitivity of particles to nAbs, however, the increased infectivity of high 
density G451R viruses does not explain their heightened sensitivity to 
antibody-dependent neutralisation. 
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Figure 5-8 Association between JFH-1 particle density and 
sensitivity to neutralising antibodies.  
JFH-1 wt (closed circles) and G451R (open circles) were separated on 
an iodixanol gradient as detailed in Figure 5-5 and the fractions tested 
for their sensitivity to neutralisation by pooled HCV infected patient IgG 
(10µg/ml). Data is expressed as percent neutralisation calculated by 
comparing infectivity in the presence of HCV negative IgG. A positive 
correlation was observed between JFH-1 particle density and 
neutralisation by pooled patient IgG, *** p=<0.0001 (unpaired t-test). 
Error bars indicate standard deviation from the mean (n=4).  
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5.7 Discussion.  
We have demonstrated that a cell culture adaptive mutation in E2 has 
pleiotropic effects on HCV interaction(s) with SR-BI, CD81 and nAbs. JFH-1 
G451R infectivity was not enhanced in Huh-7.5 cells transduced to over-
express SR-BI and was insensitive to anti-SR-BI and HDL treatments (Figure 
5-1), suggesting a reduced requirement for SR-BI during entry. Definitive 
evidence of SR-BI independence is hampered by the lack of SR-BI negative 
permissive cell lines. We failed to detect any effect(s) of the G451R mutation 
on sE2 interaction with CHO cells expressing SR-BI (Figure 5-3B & C), 
however, soluble forms of E2 may not recapitulate the interaction of virus 
particles with SR-BI.  
 
As SR-BI over expression enhances JFH-1 focus size (Figure 4-3) we 
hypothesise that it may have a key involvement in direct cell-cell transmission 
(314). We were interested to study this route of transmission for JFH-1 wt and 
G451R using the recently developed ‘infectious centre assay’ (ICA) (314). 
However, the ICA is reliant on efficient antibody neutralisation of particles as 
they are released into the culture media, thereby eliminating cell-free 
transmission. In the absence of efficient neutralisation it is difficult to 
differentiate between cell-free and direct cell-cell routes of transmission. We 
observed an apparent 2 fold increase in cell-cell transmission from JFH-1 
infected producer cells to naïve target cells over expressing SR-BI in the 
infectious centre assay (data not shown). However, as our current neutralising 
agents are relatively inefficient at perturbing JFH-1 wt infection (Figure 5-7) 
the data was difficult to interpret. To fully address the role of SR-BI in cell-cell 
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transmission we will need to overcome these technical challenges in the 
future. 
 
CD81 is a critical co-receptor for HCV particle entry (179, 202), the mutant 
virus demonstrated a 10-fold increase in the sensitivity to neutralisation by 
hCD81 LEL, suggesting an increased affinity of the gps for CD81 (Figure 
5-2C). Indeed, G451R sE2 demonstrated increased binding to CHO-CD81 
and hCD81 LEL, supporting this conclusion (Figure 5-3 & Figure 5-4). The 
observation that G451R demonstrated a reduced sensitivity to neutralisation 
by anti-CD81 mAbs than wt virus, is consistent with an increased affinity of 
G451R glycoproteins being able to more effectively compete with sub-
saturating levels of mAbs to interact with surface expressed CD81 (Figure 
5-2A & B). Mutations in CD81 reported to prevent interaction with E2 (84, 99) 
abolished the binding of both JFH-1 wt and G451R sE2 (Figure 5-4B), 
suggesting that the interface between JFH-1 G451R E2 and CD81 is 
unaltered and the viral phenotype may simply reflect a greater affinity of the 
gp with the co-receptor. Studies with HCVpp suggest that the CD81 binding 
site on E2 involves three discontinuous regions (81, 237, 265) and G451R is 
located immediately downstream of one such region G436WLAGLFY (81). 
Thus, the adaptive mutation may directly modulate E2 affinity for CD81. Our 
data suggest an important role for position 451 in JFH-1 E2 coordination of 
particle interaction with SR-BI and CD81 and highlight the importance of 
studying mutant gp association with multiple viral co-receptors.   
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Numerous reports have used density gradient centrifugation to study the 
association of plasma or serum-derived HCV with the major VLDL apoproteins 
(ApoB-100 and ApoE) (8, 233, 313). Recent data implicates VLDL synthesis 
in HCV particle assembly and/or release, suggesting that HCVcc particles 
interact with lipoproteins in an analogous manner to blood-derived virus (63, 
109, 131, 180, 224). Nielsen et. al. reported that iodixanol density gradient 
centrifugation preserved HCV-VLDL interactions (233) and we employed this 
technique to investigate the relationship between JFH-1 particle density and 
infectivity. Zhong et. al. reported an altered relationship between JFH-1 
G451R buoyant density and infectivity, with high density mutant virus 
demonstrating greater infectivity than wt (352). Similar data was observed with 
iodixanol density gradient separation (Figure 5-5 B). Importantly, analysis of 
particle number(s) by quantitative RT-PCR demonstrated a comparable 
distribution of wt and mutant viruses (Figure 5-5 A), suggesting that both 
viruses associate with lipoproteins in a comparable manner. Analysis of the 
specific infectivity throughout the density gradient suggests that the G451R 
mutation increases the infectivity of higher density particles whilst reducing 
that of low density particles (Figure 5-5 C). Determining how the cell culture 
adaptation alters the relationship between particle density and infectivity, will 
require a better understanding of the contribution lipoprotein components 
make to particle infectivity.  
 
Lipoproteins have been implicated in HCV entry and particle interaction(s) 
with SR-BI (9, 63, 190). However, we failed to observe any association 
between infectious particle density and responsiveness to SR-BI over-
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expression or receptor ‘neutralisation’ for JFH-1 wt or G451R (Figure 5-6). 
These data do not discount the role of lipoproteins in the primary engagement 
between virus and receptors, however, it suggests that the ‘functional 
outcome’ i.e. entry, is principally driven by the viral gps. This interpretation is 
consistent with our observations using plasma derived J6/JFH virus and 
murine SR-BI (Figure 4-5  & Figure 4-4). HCVpp assembly is not thought to be 
dependent on host lipoproteins and offers a tool to dissect the role of the 
adaptive G451R mutation in viral entry. However, E1E2 gps with the G451R 
mutation failed to generate infectious HCVpp (Ke Hu, personal 
communication).  
 
The heightened sensitivity of JFH-1 G451R to neutralisation is not confined to 
hCD81 LEL; IgG from six HCV infected individuals inhibited JFH-1 G451R 50-
fold more effectively than wt (Figure 5-7A-G). The polyclonal IgG was isolated 
from patients infected with HCV genotypes 1 or 3 and most likely reflects a 
mixture of antibodies specific for diverse conformation-dependent epitopes. In 
addition, G451R was >10 fold more sensitive to neutralisation by anti-E2 mAb 
3/11 (Figure 5-7H), which is specific for amino acids 412-423 (130). 
Experiments to assess the binding of polyclonal HCV+ patient IgG and 3/11 to 
immobilised JFH-1 wt and G451R sE2 by enzyme immunoassay found no 
differences (data not shown). However, sE2 may not be an accurate mimic of 
epitope availability on a native virus particle (67, 101, 148).  
 
We hypothesised that virus association with lipoproteins reduces the efficacy 
of nAbs. Taking particle density as a measure of lipoprotein interaction(s) we 
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demonstrate that low density JFH-1 has reduced sensitivity to HCV+ patient 
IgG neutralisation (Figure 5-8), showing a range of neutralisation values from 
20-80% between the densities of 1.04-1.14g/ml. The data support a model 
where lipoproteins obscure critical epitopes from nAbs and, since the majority 
of infectious JFH-1 particles are of low density (Figure 5-5), this may explain 
their insensitivity to nAbs (Figure 5-7). The mechanism by which this occurs is 
unknown, however lipoproteins may restrict the access of antibodies to E2 or 
promote the stabilization of virus particles. Our findings are consistent with 
observations reported with serum derived HCV (8, 180, 312), where 
Thommsen et. al. reported that apoprotein-B-100 associated virus failed to 
precipitate with polyclonal HCV+ IgG (313). Similarly, Molina et. al. reported 
that serum virus infectivity was neutralised with anti-CD81 antibodies targeting 
the host cell, whereas infectivity was resistant to hCD81 LEL, suggesting a 
reduced exposure of CD81 binding epitopes on circulating particles (217). 
 
The work covered in this chapter has been published in the Journal of 
Virology -  Grove, J., S. Nielsen, J. Zhong, M. F. Bassendine, H. E. Drummer, 
P. Balfe, and J. A. McKeating. 2008. Identification of a residue in hepatitis C 
virus E2 glycoprotein that determines scavenger receptor BI and CD81 
receptor dependency and sensitivity to neutralizing antibodies. J Virol, 84, 
JVI.01569-08. 
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6 Discussion and conclusions. 
6.1 SR-BI and HCV attachment and entry. 
It is becoming clear that the concept of a virus particle targeting and entering 
a host cell by interacting with a single receptor is outdated. Findings from 
across the field of virology suggest that a large proportion of viruses engage a 
series of co-receptors in directing their entry into a permissive environment. In 
many cases virus entry is dependent on a sequence of interactions with each 
step facilitating the next (184, 194, 291, 293). The attachment and entry of 
HCV is revealing itself to be one of the more intricate pathways currently 
under investigation, with at least three membrane proteins implicated. In this 
study we attempted to characterise the role of SR-BI in HCV entry, the 
following section discusses our findings in the context of what is already 
known about HCV attachment and entry. 
 
Investigating the role of CD81 and CLDN1 in HCV entry has been facilitated 
by the availability of cell lines that do not express either respective receptor 
(91, 101, 202, 314). Studies to address the role of SR-BI are hampered by the 
lack of any such cell line. We have reported that primary human sinusoidal 
enodothelial cells do not express SR-BI, however exogenous expression of 
SR-BI does not confer permissivity to HCVpp infection (257). We and others 
have used SR-BI specific antibodies to inhibit HCV infection (Figure 4-6Figure 
5-1) (60, 120, 139, 346), these findings are consistent with SR-BI having a 
role in HCV entry. It has also been reported that siRNA silencing of SR-BI 
reduces HCVcc infection (346). Furthermore, using Huh-7.5 cells transduced 
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to over express SR-BI we were able to demonstrate that SR-BI levels are a 
limiting determinant of HCV infection. SR-BI is predominantly expressed in the 
liver, indeed if there is a critical level of SR-BI expression required for efficient 
particle entry this may contribute to HCV hepatotropism (161, 257).  
 
Particle associated apoproteins have been implicated in the binding of HCV to 
SR-BI, however we found no evidence to suggest that the relationship 
between HCV and SR-BI is defined by anything other than a specific 
interaction between particle and receptor. We observed no difference in SR-BI 
dependency between particles of a low and high density, or those derived 
from cell culture and infected animal plasma (Figure 5-6 & Figure 4-5). 
Moreover, murine SR-BI did not enhance HCVcc infection (Figure 4-4), 
despite its ability to recapitulate the interactions of human SR-BI with its 
natural ligands. Current data suggests that HCV envelope protein engages 
SR-BI via HVR-1 (hyper variable region-1) (25, 274). This N-terminal domain 
is believed to be under selection from neutralising antibodies resulting in high 
antigenic variance (320, 326). However, basic residues are maintained at 
specific positions within HVR-1 and removal of this globally basic 
characteristic significantly impairs the infectivity of HCVpp (57, 240). It has 
been reported that SR-BI/II has broad pattern recognition abilities and that this 
is important for the invasion of some bacterial pathogens (246, 323). 
Therefore it is possible that HCV exploits this function, allowing redundancy 
within the HVR-1 which in turn enables escape from neutralising humoral 
responses. There has yet to be a definitive study demonstrating which 
residues of HVR-1, or indeed elsewhere within E2, are critical for HCV-SR-BI 
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interactions and we are preparing to carry out a series of experiments to 
address this.  
 
It has been previously shown that antibodies specific to SR-BI and CD81 
block HCV infection in a synergistic manner, suggesting that they function co-
operatively during HCV entry (139, 346). Our studies using JFH-1 G451R 
have for the first time shed light on an inter-dependence between HCV 
interaction with SR-BI and CD81 (Figure 5-1 & Figure 5-2). Taken together, 
these data point towards sequential receptor engagement by HCV, much like 
that seen with other viruses (184, 293, 315, 335).  It is believed that HCV 
interaction with CD81 occurs after a particle has bound to the cell surface (31, 
91, 346). Indeed Flint et. al. demonstrated that particle neutralisation by 
hCD81 LEL can only occur post binding (101), suggesting that HCV 
attachment primes particle envelope proteins for CD81 engagement. Evans 
et. al. reported that HCVcc particles bind to CHO-SR-BI cells whilst not to 
cells expressing CD81 or CLDN1 (91). 
 
We hypothesise that HCV engagement of SR-BI precedes and facilitates 
further interactions with co-receptors such as CD81, indeed, many of the 
epitopes exposed on sE2 bound to SR-BI are critical for CD81 binding ( 
 
Figure 3-3). Building on this model, the G451R mutation may cause a 
conformational change that primes E2 to interaction with CD81 and therefore 
negates the requirement for prior attachment to SR-BI. In support of this we 
demonstrate that JFH-1 G451R infectivity is less dependent on SR-BI (Figure 
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5-1), better able to engage CD81 (Figure 5-2Figure 5-3Figure 5-4) and is 
highly susceptible to polyclonal neutralising IgG (Figure 5-7) suggesting an 
alteration in the conformation of E2.  
 
Such a hypothesis is not unprecedented, primary attachment of HIV to CD4+ 
lymphoid cells promotes a conformational change in the viral envelope 
protein, gp120, which exposes epitopes that are critical for later stages of 
entry (273, 315, 335). As a result, CD4 expression levels limit HIV entry and 
cell culture adaptation leads to viruses with reduced dependence on CD4 and 
a heightened sensitivity to nAbs (13, 38, 86, 129, 249). Similar observations 
have been made using mutant respiratory syncytial virus (196). Over 
expression of SR-BI enhanced JFH-1 infection to greater extent than J6/JFH, 
suggesting strain specific differences in SR-BI dependency. Given our 
findings using JFH-1 G451R it will be interesting to investigate how this 
phenotype correlates with particle CD81 engagement and sensitivity to 
neutralising antibodies.   
 
HDL (high density lipoprotein) enhances HCVcc infection, this process is 
thought to involve SR-BI mediated cholesterol exchange, followed by the 
liberation of apoC-I from HDL (25, 79, 324, 325). Recent reports suggest that 
apoC-I integrates into HCV particles and enhances attachment and fusion 
events (79, 210, 211). Notably, JFH-1 G451R did not respond to supplemental 
HDL (Figure 5-1), this is most likely linked to its lower dependence on SR-BI. 
Based on our current understanding, it is difficult to speculate on the 
mechanisms by which apoC-I promotes infection, however our data suggests 
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that E2 determines the relationship between apoC-I and HCV particles, and 
this is closely linked to SR-BI engagement.  
 
6.2 Antibody mediated neutralisation of HCV. 
A virus particle is considered to be ‘neutralised’ when its infectious potential 
falls beneath the threshold of detection (152). There are varied mechanisms 
by which antibodies may neutralise virus particles, including; the aggregation 
of virions, inhibition of virus-receptor interaction(s) and prevention of viral 
penetration events such as fusion (152, 256). The varied modes of 
neutralisation are summarised in Figure 6-1.  
 
For each mechanism, neutralisation requires a specific interaction between an 
antibody paratope with its respective epitope and in most cases the efficiency 
of neutralisation by any given antibody is a function of its ability to bind a 
particle (54). The efficiency of this binding is determined by i) paratope-
epitope affinity ii) antibody concentration and iii) epitope availability (152, 
256). The most prevalent modes of antibody mediated neutralisation are 
believed to be inhibition of particle attachment and, in the case of enveloped 
viruses, prevention of membrane fusion (152, 256). Our findings with JFH-1 wt 
and G451R HCVcc will be discussed from this perspective. 
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Figure 6-1 An overview of antibody dependent neutralisation of virus 
infectivity.  
“Virions are represented as spiked circles, cellular receptors as a blue 
semicircle mounted on an arrow, IgG as a Y, and blocked events as an arrow 
carrying an X mounted in a red circle. A. Antibody aggregates virions and 
reduces the number of infectious centres. The fraction shown (1/2) represents 
the loss in infectivity. B. Antibody that mimics cell receptor ligation binds 
virions and leads to the disruption of the virion capsid (red lightning) and 
premature release of the genome. C. Antibody inhibits virion attachment by 
blocking receptor engagement. D. Antibody inhibits fusion occurring inside an 
endocytotic vesicle (illustrated) or at the cell membrane (not shown). E. 
Antibody binds to a cell-surface protein and results in the transduction of a 
signal into the cell (red lightning) that aborts the infection by modification of 
the replication complex. F. Post-entry neutralisation by transmission of an 
allosteric signal via the virus surface proteinto the virion core (shown as red 
lightning). The core is released into the cytoplasm but is defective and unable 
to replicate. As in (E), this process is poorly understood. G. Transcytosing IgA 
antibodies (represented as a double-ended Y) neutralise virus when their 
respective vesicles fuse. H. Antibody binds nascent virions and blocks their 
budding or release from the cell surface” Taken from Reading et. al. (256) . 
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There are various models of how antibody binding prevents virus attachment, 
entry and penetration, the most simplistic view is of a particle coated with 
antibodies unable to function due to stearic hindrance exerted by the antibody 
shell (54). However, neutralisation efficiency does not necessarily directly 
correlate with the degree of antibody coating, indeed in some cases particles 
saturated with mAb remain infectious (97). Therefore more sophisticated 
models have been developed to accommodate such experimental data.  
Multiple hit and occupancy models of neutralisation draw upon the concept 
that virions carry numerous copies of glycoprotein(s) required for virus entry, 
however particle entry may only require a fraction of the total number to be 
functional (151). Therefore, a particle can tolerate antibody mediated 
inactivation of multiple envelope proteins without any appreciable reduction in 
infectious potential. Experimentally, this phenomena manifests itself as a lag 
in neutralisation, whereby at lower antibody concentrations there is no 
detectable inhibition (105, 152).  
 
The importance of epitopes targeted by humoral responses cannot be 
overlooked. Ligation of some epitopes may exert moderate to weak 
neutralisation by partial inhibition of envelope protein function. Other, so called 
critical epitopes, contribute directly to events such as receptor engagement; 
blocking of these will render an envelope protein completely inactive (152). 
Consequently, antibodies that target critical epitopes can exhibit strong 
neutralisation at low occupancy; that is to say relatively few epitopes are 
‘occupied’ per particle (228). It has been reported that for some viruses the 
binding of a single antibody is sufficient to inactivate a particle, in these cases 
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it is believed that ligation of a critical epitope causes a catastrophic 
conformational change rendering the particle non-infectious (333). This single 
hit model results in a linear relationship between antibody concentration and 
neutralisation with no lag in efficiency (105, 152). 
 
The shape of the neutralisation curve observed for JFH-1 G451R (Figure 
5-7G), is consistent with a multiple hit model of neutralisation. No inhibition 
was detectable at IgG concentrations below 1$g/ml, whereas complete 
neutralisation was achieved at 3$g/ml. These data suggest a threshold in IgG 
concentration at which the number of functioning envelope proteins per 
particle drops below the level required for efficient infection. The shape of the 
curve is also consistent with a high degree of neutralising epitope availability, 
this supports our hypothesis of the adaptive mutation causing a 
conformational change within E2 (page 156). In contrast JFH-1 wt is relatively 
insensitive to neutralisation by HCV+ IgG, resisting inhibition over a 100$g/ml 
range, eventually reaching a plateau at 80% neutralisation (Figure 5-7). 
Assuming that JFH-1 wt and G451R particles carry the same number of 
envelope proteins, this observation suggests that JFH-1 wt limits epitope 
exposure such that even at high IgG concentrations a subset of virions 
possess sufficient functioning envelope proteins to perform entry. 
 
A number of viruses are reported to use specific protein conformations to 
obscure critical epitopes (38, 73, 264), indeed another member of the 
Flaviviridae, West Nile Virus (WNV), was recently shown to limit epitope 
availability resulting in resistance to nAb. The envelope proteins on WNV 
162 
undergo proteolytic cleavage during egress, leading to a particle 
rearrangement and maturation, however this process is not essential for 
infectivity. Nelson et. al. demonstrated that mature WNV particles are up to 
95-fold more resistant to anti-envelope mAb and that this could be attributed 
to reduced exposure of certain epitopes (228). However, describing HCV by 
analogy with other viruses only extends so far, our data suggests that HCV 
association with lipoproteins renders particles more resistant to neutralisation 
(Figure 5-8). We do not know whether lipoprotein components themselves 
obscure epitopes or if they simply stabilise particle structure, in either case 
HCV appears to have adopted a unique mechanism of evading host humoral 
responses.  
 
Lipoprotein association and epitope concealment, however, are not the only 
strategies employed by HCV to avoid nAbs. Recent reports indicate that B 
cells and dendritic cells are capable of uptake and cross-presentation of HCV, 
interestingly, SR-BI has been implicated in both cases (21, 23, 294). In B 
cells, internalised particles are shielded from nAbs and transfer of HCV from B 
cells to human hepatoma cells enhances infectivity by 30 fold (294), indicating 
that B cells may offer HCV safe and efficient passage to the liver. As 
discussed previously, HCV is also capable of direct cell-cell transmission 
(314), similar to that reported for other viruses (134, 137, 284). It is 
conceivable that in an organ such as the liver, cell-cell transmission may 
represent the major route of infection within a host, indeed if this is the case it 
will have major implications for those hoping to treat HCV with monoclonal 
antibody therapies (146). 
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Given our and other’s findings regarding the ability of HCV to evade nAb 
responses, the lack of clear evidence supporting a role for humoral immunity 
in controlling infection is unsurprising (87, 140, 182, 295, 327). Indeed the 
relatively late development of anti-HCV antibodies (64), may be partly 
attributable to the low availability of critical epitopes on circulating particles. 
However, there remains a discrepancy between in vivo studies and 
experiments using the HCVpp and HCVcc models of virus entry. Antibodies 
isolated from patients have been shown to efficiently neutralise HCVpp (182, 
245), moreover there have been numerous accounts of anti-E2 mAbs 
inhibiting both HCVpp and HCVcc infectivity (130, 145, 172, 236, 307, 308). 
However, observations in vivo (87, 140, 182, 295) and our findings using JFH-
1 wt suggest that HCV may be relatively resistant to humoral immunity, 
indicating that more work is necessary to understand the relationship between 
authentic HCV particles and neutralising antibodies. Our findings using JFH-1 
G451R demonstrate a link between particle sensitivity to neutralising 
antibodies and SR-BI dependency. Therefore, we are interested in examining 
the relationship between these two characteristics in different strains of 
HCVcc; J6/JFH exhibits a lower dependence for SR-BI (Figure 4-2), this 
phenotype may also reflect particle sensitivity to neutralisation. 
 
HCVpp are unlikely to mimic the structure of lipo-viro-particles and 
recapitulate natural HCV envelope protein conformation(s). Consequently they 
may not be suitable for assessing antibody mediated neutralisation. Indeed, 
experiments using HCVpp have suggested that blocking epitopes necessary 
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for HCV-CD81 interaction is a common feature of neutralising antibodies (130, 
145, 236, 237, 308); however our findings pose a question over the 
accessibility of these epitopes on HCVcc particles.  Furthermore, we observed 
that cell culture adaptation of JFH-1 altered particle sensitivity to nAbs, 
therefore studies quantifying humoral immunity using HCVcc need to ensure 
that similar mutations have not occurred. However, a large proportion of cell 
culture adaptations reported so far fall within the non-structural genes of HCV 
(141, 144, 269) and therefore would not be expected to alter the relationship 
between particles and antibodies. 
 
It is clear that the currently available in vitro models of HCV replication are 
limited in their ability to recapitulate the characteristics of particles circulating 
within an infected host. Therefore it is necessary to develop innovative 
systems to overcome the disparity between observations made in vitro and in 
vivo. A recent study by Vanwolleghem et. al. used immuno-compromised mice 
bearing humanised livers as a target for infection with patient serum derived 
HCV (322). Mice that had been passively immunised with polyclonal IgG 
isolated from a chronically infected patient were resistant to infection with 
HCV derived from the same source. This suggests that the infected patient 
had raised a neutralising antibody response, an observation that will 
encourage those hoping to develop a B-cell vaccine. In the future, infectious 
systems such as humanised mice will allow us to validate observations made 
using cell culture models, paving the way to a better understanding of how 
HCV establishes persistence in such a large proportion of cases. 
 
165 
6.3 HCV lipo-viro-particles. 
As discussed throughout this thesis, HCV virions exist as LVPs, containing 
viral structural proteins, dietary lipids and apoproteins (8, 63, 109, 131, 233, 
312). It is unclear what contribution the host lipoprotein moieties make to HCV 
infection. However, several reports have demonstrated that apoproteins are 
essential for HCV particle assembly (63, 109, 131, 224) and may play an 
important role in virus attachment and entry (9, 63, 190, 211). In this way 
apoproteins may be thought of as functional structural components of HCV 
particles.  
 
This does, however, present difficulties in modelling the structure of a HCV 
lipo-viro-particle. The particles of related Flaviviruses such as Dengue have 
highly ordered ‘smooth’ structures, with the viral envelope proteins lying flat 
across the membrane surface (222, 247); a classical Flavivirus particle is 
analogous to a golf ball. These structures are comprised of an ordered lattice 
of viral glycoproteins (222, 247), in the case of HCV it is difficult to imagine 
how apoproteins, some of which are large (>500kDa), could be incorporated 
into such an arrangement.  
 
HCV LVPs act as metabolically functional lipid carriers (77), demonstrating 
lipoprotein like properties and structure. Additionally, reports suggest that 
HCV LVPs are not simply virions with lipoproteins attached to their surface (8, 
77). Therefore the structure of HCV LVPs must reconcile these disparate 
characteristics, allowing them to function as virus particles and lipoproteins 
simultaneously. 
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Particle density is believed to be determined by lipid composition; lower 
density HCV virions have a higher lipid content and therefore may be 
regarded as the ‘most lipoprotein like’ form. Low density HCV have the 
highest specific infectivity (45, 179, 180) and we have shown that particle 
density correlates with sensitivity to neutralising antibodies (Figure 5-8). 
Taken together these observations suggest that adopting a lipoprotein like 
formation promotes HCV infection, and possibly stabilises the virion 
glycoproteins in a manner that reduces epitope availability. A number of 
apoprotein species can be found in HCV LVPs, indeed apoC-I is thought to 
enhance infection (79, 210, 211), however it is not known how apoproteins 
function within an infectious particle. Understanding the role of apoproteins 
within circulating HCV particles will be key to determining the relationship 
between particle density and infectivity. 
 
Figure 6-2 displays a model structure of a HCV LVP; this particle has both 
virion and lipoprotein like characteristics. The envelope proteins lie flat within 
the membrane surrounding the capsid, however the outer leaflet of the virion 
envelope is fused with the lipoprotein lipid monolayer. This proposed structure 
would confine the viral glycoproteins to the virion envelope bilayer, whereas 
the very large structural apoprotein, apo-B100, resides within the triglyceride 
core of lipoprotein (321) and should not diffuse into the virion. However, the 
smaller exchangeable apoproteins reside within the lipoprotein lipid monolayer 
(321), allowing their diffusion throughout the particle and interaction with viral 
glycoproteins. The areas of the viral envelope proteins shaded in green 
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represent the hyper-variable regions, as discussed earlier these are under 
sustained immunological selection and are likely to be accessible. Other 
critical regions of E2 remain buried within the LVP, reducing epitope 
exposure, we hypothesise that a conformation change within E2 upon 
interaction with SR-BI leads to the exposure of these regions (Figure 6-2B). 
168 
 
Figure 6-2 Model lipo-viro-particle.  
A. Cartoon representation of a LVP. B. Proposed model of LVP-SR-BI 
interactions.  
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The G451R mutation disrupts the relationship between particle density and 
infectivity, suggesting that E2 contributes to the relationship between HCV 
and lipoprotein components. However, HCV pseudo-particles are not thought 
to mimic lipoprotein association and yet remain infectious, therefore it is clear 
that envelope proteins function outside of the context of a LVP.  Given JFH-1 
G451R’s reduced dependency for SR-BI it is tempting to speculate that 
lipoprotein association promotes viral entry events closely linked to SR-BI and 
that the adaptive mutation allows HCV to negate these processes. For 
instance, it is possible that associated lipoproteins define initial particle 
attachment, allowing specific interaction(s) between the viral glycoproteins 
and SR-BI.  
 
It is becoming clear that to understand the interaction of HCV particles with 
cellular receptors and the immune system it will be necessary to unravel the 
relationship between HCV and host lipoproteins. In further characterising HCV 
attachment and entry the principal challenge will be to define the functional 
constituents of an infectious lipo-viro-particle.  
 
6.4 Closing remarks. 
It has been three years since the advent of the HCVcc system and much has 
been achieved in this short time. Work with this novel system has fallen to 
three areas: investigating HCV entry, understanding the viral proteins in the 
context of the entire viral life cycle and elucidating the events surrounding 
HCV assembly and release. In this study we have used the HCVcc system to 
characterise the role of SR-BI in virus attachment and entry. More importantly, 
170 
we have, for the first time, demonstrated an interplay between HCV particle 
interaction with co-receptors, neutralising antibodies and host lipoproteins. We 
hope to continue this line of investigation, focussing on how HCV LVP 
composition and structure defines envelope protein exposure, receptor 
engagement and ultimately infectivity. 
 
In continuing our work it is important to continuously evaluate the techniques 
we use. Cell culture proficient HCV is a very powerful tool, however we must 
make efforts to understand how our findings relate to the situation within a 
HCV infected individual. Much of the observations documented in this thesis 
are virtue of a lab adapted virus and, although fascinating, JFH-1 G451R is 
emblematic of the problems faced by those using a cell culture proficient HCV. 
Additionally, some of the inherent limitations in the HCVcc system lie in the 
cells used to support infection; Huh-7.5 cells are a very good target for 
infection but doubts remain over how well they represent human hepatocytes. 
Therefore, the ongoing attempts to propagate patient derived HCV in primary 
human hepatocytes (51, 216, 217) are an important aspect of HCV research. 
Consolidating observations from cell culture, animal models and HCV infected 
individuals will pave the way towards more effective treatments in the future.  
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